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LAY ABSTRACT 
 
Breast cancer remains one of the most common causes of death amongst women today.  
Worldwide approximately 1.3 million women are diagnosed as having breast cancer 
every year. Much research has been done in trying to unravel the cause and behaviour of  
breast cancer and hormonal influences are known to play a role. In particular, two 
hormones known as growth hormone (GH) and insulin-like growth factor (IGF-1) have 
been found to play an important role in breast cancer growth and development. It has 
been found that women with breast cancer have higher levels of IGF-1 in their blood 
compared with women without breast cancer. Further studies have shown that if IGF-1 is 
added to breast cancer cells in laboratory conditions they grow rapidly. This evidence 
points to a strong link between IGF-1 and breast cancer. The majority of circulating IGF-
1 is made by the liver in response to growth hormone, but as IGF-1 is also found in most 
cells in the human body, it is uncertain whether its possible effects on breast cancer may 
be due to local production of IGF-1 by breast cancer cells or to IGF-1 circulating in the 
blood. This research aims to study the link between IGF-1, GH and breast cancer. In 
order to do this, small specimens of breast tissue will be taken from women who are 
undergoing surgery for treatment of their breast cancer. Most cells removed will be 
cancer cells, but a rim of normal cells will surround them. I will then look at the different 
levels of IGF-1, growth hormone and other related hormones produced by the cancer or 
normal cells. During further research, I will aim to keep these cells alive for a few hours 
and see how they respond when various hormones are added to them. This research will 
give us more information about the hormonal control of breast cancer growth and may 
lead to novel treatments for breast cancer in the future.
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1. Introduction 
 
 
 
1.1 The GH-IGF-1 axis  
 The growth hormone /insulin-like growth factor-1 (GH/IGF-1) axis plays an essential 
role in the development of the breast by regulating cell proliferation, differentiation 
and apoptosis. GH is a peptide hormone synthesized and secreted mainly by the 
anterior pituitary gland in response to hypothalamic factors. Three hypothalamic 
peptides, growth hormone-releasing hormone (GHRH), the endogenous GH 
secretagogue (GHS) ghrelin and somatostatin, generally control GH release from 
somatotropes. GHRH and ghrelin, stimulate its release, while somatostatin is 
inhibitory. Although these hormones are known to be produced in the hypothalamus 
and stomach, a production in local tissues resulting in an autocrine/paracrine mode of 
action has been ascertained1. Binding sites for GH secretagogues are present in breast 
tissue and ghrelin exerts GH independent effects 2 although the local expression of 
ghrelin in breast is undetermined. Octreotide, a somatostatin analogue, appears to 
have antiproliferative effects in breast cancer by inhibiting GH release and therefore 
reducing IGF-1 levels3. Although several phase 1 and 2 clinical trials have 
investigated its effects, results have been variable. However a meta-analysis of all 
trials showed that in patients with metastatic breast cancer, a tumour response of over 
40% was achieved with few side-effects3.  
 
 
 
15 
 
1.1.2 Ghrelin 
 
Ghrelin is a 28 amino-acid peptide with an n-octanoylated serine at residue 3, which is 
essential for its GH-releasing activity. It was originally identified from rodent 
stomach tissue, based on its ability to bind with high affinity and specificity to the GH 
secretagogue receptor (GHSR)2. Likewise in the human, ghrelin is synthesized and 
secreted from a distinct endocrine cell type found in the submucosal layer of the 
stomach4.  It is similarly synthesized and secreted from other parts of the 
gastrointestinal tract, such as the duodenum, ileum, caecum and colon5.   Several post-
transcriptional and post-translational variants of ghrelin have been reported. Des-
octanoylated ghrelin is a non-modified molecular form of ghrelin and is unable to 
activate GHSR expressing cells as it lacks the Ser3 octanoic acid2. A 27 amino acid 
splice variant that has lost the glutamine 14, known as Des-Gln14-ghrelin has also 
been identified and shown to have similar biological actions to full-length ghrelin6.  
Ghrelin acts directly on the anterior pituitary gland to stimulate GH release, and in 
vivo studies in humans involving intravenous injections of ghrelin demonstrate that 
the GH response to ghrelin is greater than that to GHRH 7. However, despite its potent 
effect on GH release, there is some doubt over the primary role for ghrelin in the 
regulation of GH secretion, following a report indicating that no specific phenotype 
was observed in a ghrelin knockout mouse8. In vitro ghrelin has been reported to 
cause inhibition of proliferation of breast cancer cell lines, albeit at supraphysiological 
concentrations2. Many recent reports have suggested that ghrelin has a physiological 
effect not only on GH release, but also on gastric acid secretion and gastric motor 
activity. Ghrelin is also known to have an appetite-inducing function with 
experiments demonstrating ghrelin-induced adiposity9. It has a major stimulatory 
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effect on appetite in rat models, and plays a physiological role in meal initiation in 
humans10. Some studies suggest that sequence variations in the ghrelin gene may be 
part of the aetiology of human obesity11. 
Ghrelin and growth hormone secretagogue receptor (GHSR) have both been found to 
be expressed in normal breast tissue and breast cancer12;13. The GHSR is thought to 
mediate growth inhibitory effects on breast carcinoma cells in vitro14. 
 
 
 
 
1.2 IGF-1 and 2 
IGF-1 consists of 70 amino acids (7.65 kDa) and IGF-2 of 67 (7.47 kDa). They share 
62% homology in amino acids sequence and there is 40% homology between the 
IGFs and proinsulin15,16. As their name suggests they are growth factors with growth 
promoting properties in numerous tissues and are present in high concentrations in 
serum. However, unlike insulin, IGF-1 and IGF-2 are expressed mainly from the liver 
during adult life, and IGF-1 mediates most of the growth effects of growth hormone. 
Although both IGFs are known to be mitogens, IGF-2 is much more active during 
prenatal life than IGF-1, whereas IGF-1 is the principle regulator of linear growth. 
IGF-1and 2 are unique as peptide growth factors. In addition to autocrine/paracrine 
functions demonstrated in numerous tissues, it serves as an endocrine hormone 
promoting postnatal somatic growth and maintaining lean tissue mass.  
The IGFs circulate in a molar ration of 2:1 (IGF-2:IGF-1)17.  They bind with high 
affinity to six related IGF binding proteins18 (IGFBP1-6) with ninety nine percent of 
IGF-1 and IGF-2 bound in serum to IGFBPs19. Less than 1% of IGF-1 and IGF-2 
circulate in an unassociated form. 
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IGFBP-3 is the most abundant IGFBP in adults and 90% of circulating IGF-1 is 
carried in a complex with IGFBP-3 and an acid labile protein20. The smaller 
complexes are able to pass the vascular endothelial barrier and therefore may be 
important modulators of IGF-1 activity at the cellular level21. IGFBPs especially 
IGFBP-3 have independent effects on cell growth, for example IGFBP-3 has pro-
apoptotic activities both dependent on and independent of p5322. IGFBP-3 may 
indirectly influence tumourigenesis by binding IGF-1 and thereby inhibiting the 
mitogenic effects of IGF-1. It may also directly affect tumourigenesis by its own anti-
proliferative and pro-apoptotic effects. In this way IGFBP-3 is thought to play a 
cancer protective role.  
The IGFBPs affect cells in both an IGF-dependant and –independent manner. By 
binding IGF-1 and IGF-2 they serve as circulating reservoirs transporting the IGFs, 
prolonging their half-lives, and regulating access of the IGF ligands to the IGF 
receptors. The same binding protein can have both inhibitory and stimulatory effects 
depending on its concentration, phosphorylation status and proteolytic fragmentation. 
In experimental systems the addition of IGFBPs generally inhibits the activities of 
IGFs, presumably by sequestering a high proportion of the free growth factor23. In this 
way IGFBPs act as regulators of IGF action and increase their half-life. 
 
 
 
 1.2.1 IGF-1 receptor 
There are two transmembrane receptors IGF-1 receptor and IGF-2 receptor, the first 
of which resembles the insulin receptor to some extent.  IGF-1 exerts its effects on 
cellular proliferation and apoptosis via the IGF-1 receptor(IGF-1R), which is a 
transmembrane tyrosine kinase receptor and is over expressed in breast cancer 
tissue24.  The IGF-2 receptor has a higher affinity for IGF-2 and is a mannose 6-
18 
 
phosphate receptor. The IGF-1R is transcribed from a single gene as a precursor that 
is then processed into an -subunit and a subunit. The functional receptor is a 
heterotetrameric consisting of two -subunits and two -subunits that are linked by 
disulfide bonds. The -subunits are extracellular and form the ligand-binding domain. 
The -subunits, which contain short extracellular and transmembrane segments and a 
larger intracellular segment, transmit the ligand-induced signal. Binding of the IGF-1 
to the IGF-1R causes autophosphorylation and transphosphoprylation of the -subunit 
of IGF-1R. The action of this receptor usually requires the use of intermediate 
docking proteins for the propagation of its numerous signal transduction cascades. 
IGF-1 receptor phosphorylates cytosolic proteins such as the insulin receptor 
substrate-1 (IRS-1). This protein has no intrinsic enzymatic property but is thought to 
act as a link between the activated receptor and downstream components of the 
signaling cascade. IGF1R signal transduction involves the activation of various 
intracellular signaling pathways, including the Ras/Raf/MAP kinase and the 
phosphoinositide-3 kinase pathways25 (Fig 1). There are also hybrid receptors 
between IGF-1R and insulin receptor (InsR) and it is thought that these hybrids 
behave more like IGF-1R than InsR. Thus binding of IGF-1 to IGF-1R or the hybrid 
receptor stimulates a cascade of signaling events leading to cell growth and inhibition 
of apoptosis. Abundant IGF-1 receptors exist on the surface of breast tumour cells and 
exposure to the IGFs increases their proliferation rate26. Conversely targeted 
disruption of the IGF-R gene, which suppresses the expression of IGF-1 and thus 
inhibits its function, can abolish cell transformation27.  
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Figure 1 – IGF-1 binding to IGF-1 Receptor and activation 
of intracellular signalling pathways 
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1.2.2 IGFBP protease 
 
Another component of the IGF regulatory system is the IGFBP protease system. This 
comprises of a group of enzymes that cleave the IGFBPs and therefore alter their 
ability to bind IGFs28.  IGFBP-3 protease activity is abundant in normal extracellular 
tissue29. 
Prostate-specific antigen (PSA) is an example of a well-known IGFBP specific 
protease. PSA cleaves IGFBP-3 and is thought to play an important role in metastatic 
prostate cancer30, perhaps by  increasing levels of circulating free IGF-1 and IGF-2 
resulting in proliferation of prostate cancer cells30. A number of patients with 
advanced breast cancer also have increased plasma IGFBP-3 protease activity which 
correlates with clinical stage and alterations in tumour burden due to therapy31.  
 
 
 
1.3 IGF-1 and breast tissue 
RNA extracted from breast tissue has easily detectable IGF-1 mRNA. In situ 
hybridizations show that IGF-1 mRNA is expressed in the stromal cells and not by 
normal or malignant epithelial cells32. Cullen et al also showed that IGF-1 mRNA was 
commonly expressed in fibroblasts derived from non malignant biopsy specimens33. 
This data shows that IGF-1 is expressed in normal breast tissue and is thought to play 
an important role in normal breast tissue development. 
IGF-1 is synthesised mainly in the liver under the control of pituitary growth 
hormone, which is itself controlled by growth hormone releasing hormone from the 
hypothalamus. (Fig 2) For this reason plasma concentrations of IGF-1 largely reflect  
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Figure 2 – Summary of growth hormone-IGF-1 axis demonstrating 
the production of IGF-1 and IGFBP-3 from the liver and the 
formation of the ternary complex 
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the activity of growth hormone. In fact the correlation of IGF-1 and GH has been 
found to be so reliable that IGF-1 levels in serum are used to monitor treatment with 
GH in GH deficient states20. In animals and humans, expression of both IGF-1 and 
IGF-1R are necessary for normal growth. The insulin-like growth factor family of 
ligands, receptors, and binding proteins is intimately involved in the normal growth 
and development of the human fetus and adult.  The IGF surge during puberty is 
associated with the normal development of the breast.  IGF plasma concentrations are 
also known to change with nutritional status, sex, age and oestrogen level34.  Serum 
IGF-I and IGFBP3 levels increase with age and decline after puberty, suggesting an 
age-dependant expression35. Hence, the IGF-1 concentrations may be particularly 
relevant to breast cancer risk in premenopausal women, especially as oestrogen has 
been shown to enhance the action of IGF-1 in the breast. GH that raises the circulating 
IGF-1 levels also upregulates IGF gene expression within the mammary gland36. IGF-
1 appears to be a required factor for normal mammary gland development36. In 
primates, infusion of GH alone results in a fourfold increase in mammary glandular 
size, although whether this results from direct effect of GH or induction of local 
production of IGF-I is unknown37. Regardless, development of the human mammary 
gland can be divided into several stages all of which are influenced by the GH/IGF-I 
axis and enhanced by estrogens (Fig 3). In addition IGF-I is required for ductal 
morphogenesis; in its absence mammary development does not occur even in the 
presence of estrogens38. 
However tissue IGF bioactivity is influenced not only by circulating IGF-1 and IGF-2 
levels but also by autocrine and paracrine secretion of these growth factors, and by 
IGFBP levels and IGFBP proteases. 
An IGF-related ligand can act as an autocrine growth factor for many cancer cell lines  
23 
 
Figure 3 – Diagram of stages of normal breast development 
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via the type I IGF receptor (IGF-R). The human breast is continuously exposed to the 
insulin-like growth factors (IGFs). In addition to high endocrine levels, IGF-1 and 
IGF-2 also originate from distinct cell populations within the breast itself39;40. IGFs 
are mitogenic for malignant breast epithelium. IGF-1 receptors exist on the surface of 
breast tumour cells, and exposure to the IGFs increases their proliferation rate. Until 
recently it was thought that hepatic IGF-1, acting in an endocrine manner was 
responsible for growth and development. However it is now clear that 
autocrine/paracrine production of IGF-1 is at least as important.  
 
1.3.1 IGF-1 and Oestrogen 
Considerable evidence suggests that the GH/IGF-1 axis and ER signaling act through 
a complex cross-talk mechanism to stimulate the proliferation of normal mammary 
epithelium to increase the risk of breast cancer41;42. The oestrogen antagonist 
Tamoxifen blocks IGF-1 mediated proliferation of breast cancer cells in vitro43 and 
has been used successfully in chemoprevention of breast cancer, with several studies 
showing how it reduces IGF-1 serum concentration in vivo44;45. This latter effect is 
due to several actions. Suppression of pituitary GH secretion occurs first, in part, by 
enhancing somatostatin actions46 and second by a direct inhibitory influence on IGF-1 
expression47. Tamoxifen also inhibits IGF-1 gene expression in common secondary 
sites for breast cancer metastasis47;48. Oestradiol markedly increases GH-mediated 
expression of IGF-1 mRNA in normal mammary tissue, as well as upregulating 
expression and activation of the IGF-1R in ER-positive breast cancer cells49. Indeed a 
synergy occurs between Oestradiol and IGF-1 in mediating the proliferative response 
in ER+ cells50. The expression of nearly all members of the IGF system is under 
transcriptional control of the ER. IGF has also been reported to activate ER. IGF-1 
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causes transcriptional activation of ER in human breast cancer cells, and the inhibition 
of ER action by IGFBP-1 suggests that IGF-1 signaling maybe necessary for maximal 
ER activation51. While GH is believed to be the pituitary factor responsible for 
mammary ductal morphogenesis, it has been reported that IGF-1 mimics the action of 
GH on mammary development in hypophysectomized, gonadectomized rats25.  
 
 
 
 
 
1.3.2 The role of the GH-IGF-1 axis in breast cancer 
 
The growth hormone (GH)/ insulin-like growth factor (IGF-1) axis is implicated in 
the pathogenesis of human breast cancer52. Historical data reveals that women with 
breast cancer who had undergone hypophysectomies had an improved prognosis53. 
This effect was still apparent in those who had had prior total hysterectomy and 
oophrectomy suggesting that gonadotrophin independent pituitary derived factors 
influence the behavior of breast cancer53;54. Subsequent epidemiological data have 
shown a positive association between risk of breast cancer and increased height. As 
GH and IGF-1 are major determinates of the latter, this indirect evidence suggests that 
these hormones might influence breast tumourgenisis55. Conversely, low birth weight, 
which is associated with low serum IGF-1 levels, correlates with subsequent low 
breast cancer risk56. Nutritional intake is a major determinate of hepatic IGF-1 
secretion57 and high calorie intake in childhood has been associated with a significant 
increased risk of breast cancer in later life58. Dietary restriction, which decreases the 
serum concentration of IGF-1 in both humans and rodents, reduces the incidence of 
cancer in many rodent models. A further association is provided by studies 
demonstrating serum GH concentrations to be elevated in a significant percentage of 
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breast cancer patients compared to controls59 and also to be increased in women at 
high risk for familial breast cancer60. Circulating levels of IGF-1 have been found to 
be increased in women with breast cancer compared to control subjects61. That these 
elevated levels of IGF-1 are not due to the cancer itself is discounted by a study by 
Hankinson et al62 who established a prospective link between serum IGF-1 levels and 
subsequent risk of breast cancer. An increased risk of 2.3 fold in pre-menopausal 
women was associated with circulating IGF-1 concentrations in the upper tertile of the 
normal range. This relative risk increased to 4.6 fold in pre-menopausal women less 
than 50 years old, and controlling for IGFBP-3 concentrations increases the risk to 7.3 
fold. Similarly Byrne et al observed that mammographic breast density in post-
menopausal women, which is a strong predictor of the risk of breast cancer, was 
positively correlated to plasma IGF-1 and inversely correlated to plasma IGFBP-363. 
A further paper has also shown mammographic density to be positively associated 
with IGF-1, negatively with IGF-2, but not with IGFBP-3. The study supported the 
hypothesis that endogenous hormones affect density of mammograms in 
premenopausal women, in particular showing a positive association with oestrogen 
levels and mammogram density64. High serum concentrations of IGF-1 are associated 
with an increased risk of breast, prostate, colorectal and lung cancers65. In patients 
with acromegaly, high concentrations of growth hormone stimulate production of high 
concentrations of IGF-1 and this has been associated with an increased risk of 
colorectal and breast cancer66, 67.  Most studies have focused on the risk of cancer in 
relation to serum or plasma concentrations of IGF-1, IGF-2 and IGFBP-3 and have 
shown that high IGF-1 and low IGFBP-3 predicts increased cancer risk68. In fact a 
recent paper has shown that circulating IGF-1 is positively associated with breast 
cancer risk. The association was not substantially modified by IGFBP-3 and did not 
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differ markedly by menopausal status but seemed to be confined to oestrogen-
receptor-positive tumours69. IGF-1 accelerates the progression of precancerous 
changes to invasive lesions. Therefore a decrease in serum IGF may help reduce the 
risks of breast, prostate and colon cancer, especially for members of high-risk 
families. 
 
 
1.3.3  In vitro and animal studies 
In vitro, IGF-1 exerts marked proliferative and anti-apoptotic effects on breast cancer 
cell lines15,70.Administration of IGF-1 may rescue breast cancer cell lines from 
chemotherapy induced cell death by induction of proliferation and inhibition of 
apoptosis70. Substantial evidence from animal studies also supports the view that the 
GH/IGF-1 axis plays an integral role in breast tumorigenesis. Early studies revealed a 
positive correlation between the activity of the GH-IGF-1 axis and development of 
breast tumors in mice71. Subsequently, transgenic mice that over express growth 
hormone have been shown to exhibit both mammary gland epithelial cell 
hyperplasia72 and have an increased frequency of mammary tumours, as do mice with 
over expression of IGF-1R agonists73. In contrast, ductal hypoplasia is seen in 
transgenic animals that over express a GH antagonist74. Similarly antibodies against 
the IGF-IR inhibit in vivo growth of subcutaneous breast tumours transplanted into 
nude mice75. Liver IGF-1 deficient mice with a 75% reduction in circulating IGF-1 
levels demonstrate a reduction in tumour development76. 
Whilst this evidence seems to suggest a role for the GH/IGF-1 axis in breast cancer, 
the relative importance of endocrine versus paracrine effects of GH/IGF-1 axis in the 
breast has not been investigated. It is also unknown whether GH may exert IGF-1 
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independent effects in this tissue, although GH has been shown to stimulate 
transcription of c-myc, a proto-oncogene. IGF-1 also regulates the expression of 
several genes associated with breast tumourigenisis; c-myc, VEGF, progesterone 
receptor (PgR) and cathepsin D77. 
A new antagonist of GH action, Pegvisomant, is a powerful inhibitor of GH secretion 
and may be an active anti-cancer agent. Preliminary reports suggest that Pegvisomant 
could have anti-tumour effects in several model systems78. Thus lowering serum IGF-
1 levels with Pegvisomant could directly test the contribution of endocrine IGF-1 to 
cancer biology. 
 The IGF system seems to have important implications in the treatment of breast 
cancer. The expression of IGF components has been linked to malignant 
transformation and disease progression, suggesting that this system might be an 
effective target for breast cancer therapy. There is increasing experimental evidence 
that interventions which reduce circulating IGF-1 levels reduce proliferation of breast 
neoplasms. This has increased the interest in developing novel endocrine therapies 
that target the GH/IGF-1 axis.  
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2. Hypothesis and Aims 
 
 
2.1 Hypothesis 
 
Paracrine/autocrine expression of IGF-1 within the breast is important in the growth 
of breast cancer. 
 
 
2.2 Aims 
1. Determine and quantify mRNA levels of IGF-1 and its receptor in normal and 
malignant breast tissue. 
2. Confirm mRNA expression at a protein level by immunohistochemistry (IHC). 
3. Investigate expression of putative IGF-1 responsive genes and correlation with 
IGF-1 expression. 
4. Examine the microarray gene profile to investigate IGF-1 regulated genes. 
5. Use an in vitro system of breast tissue explant incubation to determine effects of 
growth hormone on local IGF-1 expression 
6. Measure levels of IGF-1 and IGFBP3 in serum of women with breast cancer before 
and after surgery 
7. Association of IGF-1 with clinical phenotype 
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3. Materials 
 
 
3.1.1 Major 
 
Tissue Homogeniser Ultraturrax T8 – GMBH & Co, Germany. 
Rneasy RNA extraction kit, Qiagen Ltd, Crawley, West Sussex, UK. 
RNA 6000 Nano Labchip kit (RNA quantification), Agilent Technologies UK Ltd, 
Cheshire, UK. 
 
Ribogreen (RNA quantification), Molecular Probes, Amsterdam, The Netherlands. 
 
Wallac Victor2 1420 Multilabel Counter (plate reader), Perkin Elmer Life Sciences, 
Cambridge, UK. 
 
Mx4000TM RT-PCR mutiplex quantitative PCR system, Stratagene, The Netherlands. 
 
BrilliantTM plus single step quantitative RT-PCR core reagent kit, Stratagene, The 
Netherlands. 
 
Primers and probes designed by Primer Express software, ABI Perkin Elmer, 
Warrington, UK. 
 
ABC kit, Vector Labarotories, USA. 
 
NuaireTM DH Autoflow aotomatic CO2 Incubator, Triple Red Lab Technology Ltd, 
Oxfordshire, UK.  
 
Balance, Satorius 1800, Sartorius Ltd, Sussex UK. 
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MTS proliferation assay, Cell Titer 96 Aqueous One Solution Assay 
Promega,Southampton, UK. 
 
 
LDH cytotoxicity detection kit, Roche Molecular Biochemicals, NJ,UK. 
 
 
Immunofluorescence, TSATM, Perkin Elmer, USA. 
 
 
Affymetrix  U133A Chip protocol 
 
 
Gene Spring 6.0 expression analysis software 
 
 
 
 
 
 
 
3.1.2 Minor 
 
 
RNA later, Ambion (Europe) Ltd, Huntingdon, UK. 
 
 
Cryogenic 2ml vials, Corning Inc, NY, USA. 
 
 
Scalpels blade no. 10, Fisher Scientific UK, Loughborough, UK. 
 
 
Pipette tips, Starlab, Helsinki, Finland. 
 
 
24 well and 96 well microplates, Abgene UK. 
 
 
Microcentifuge tubes, Starlab, Helsinki, Finland. 
 
 
Depex mounting medium, Gerr, Canada. 
 
 
Ethanol (96%), VWR International Ltd, Lutterworth,UK. 
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Amphotericin (0.g/ml), Invitrogen Ltd, Paisley, UK. 
 
Penicillin (10mg/ml), Invitrogen Ltd, Paisley, UK. 
 
 
Streptomycin (10mg/ml), Invitrogen Ltd, Paisley, UK. 
 
 
Dulbecco’s Modified Eagle Medium, GibcoBRL, Paisley, UK. 
 
 
Bovine serum albumin, Sigma Poole. 
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 4. Methods 
 
 
4.1 Ethics 
 
This study was approved by The Local Research Ethics Committee of the 
East London and City Health Authority. All involved patients signed a 
consent form designed specifically for this study (Appendix A). Fully 
informed consent was obtained prior to collection of all samples from 
theatre, and a copy of the consent form was filed in the patient’s notes, 
given to the research department, given to the patient and also given to 
the pathology department. 
 
 
4.2 Tissue collection 
 
Samples of normal and malignant breast tissue were collected from 185 
women undergoing mastectomy or segmental mastectomy for breast 
cancer (see Appendix B – patient tumour characteristics).  The patients 
were aged 20 to 90 years old and were operated on at St Bartholomew 
Hospital. The tumours were all greater than 1cm in diameter. Smaller 
tumours were not taken as this may have affected histological results. The 
breast specimens were taken to the pathology department directly after 
removal in theatre, where a pathologist orientated the specimen and inked 
the margins. A section of normal and malignant tissue was identified 
macroscopically and dissected out. Areas of breast fat were avoided, as 
were inked areas. Normal tissue was harvested as far away from 
malignant tissue as possible. Samples were then placed immediately into 
‘RNA later’ (Ambion, UK). The samples were then snap frozen in liquid 
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nitrogen and stored at -80oC. The tumours histology was noted as either 
invasive ductal, lobular, tubular, medullary, mucinous, the tumours size, 
grade and presence or abscence of DCIS. Also the lymph node status was 
recorded along with the ER and PR status of the tumour. 
 
 
 
4.3 RNA extraction 
 
Successful extraction of RNA requires disruption of the tissues, inhibition 
RNases activity (enzymes that degrade RNA) and removal of any 
contaminating genomic DNA or proteins. 
 
All tissue samples were stablilised in ‘RNA later’ prior to archival storage 
at–80oC. Use of this reagent allows immediate stabilisation of RNA there 
by preventing any changes in gene-expression pattern that may occur 
with RNA degradation. All eppendorfs used had been previously 
autoclaved. 
 
Tissue samples of approximately 20-30mg were subsequently excised 
after removal from ‘RNA later’. Due to poor yield of RNA from adjacent 
normal breast tissue, sample size of these samples was increased to 50mg. 
Qiagen ‘Rneasy’ kit was used to extract RNA. This technique allows 
isolation of RNA molecules longer than 200 nucleotides. This therefore 
provides mostly mRNA as most RNAs less than 200 nucleotides in length 
are excluded. Lysis buffer RLT, containing guanidine thiocyanate and B-
mercaptoethanol, was used. This buffer is effective in inactivating 
RNases to allow isolation of intact RNA. Tissue disruption was achieved 
using a tissue homogeniser. 
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 4.3.1 Tissue homogenisation 
 
500µl of buffer RLT was added to 30mg of frozen tumour or 700µl RLT 
to 50mg of frozen adjacent normal tissue.  
 
A rotor ‘Ultra-turrax’ homogenizer was used to disrupt the tissues for 
approximately 20 minutes at speed setting 4. Care was taken to avoid 
over-heating and foaming. The rotor homogenizer disrupts the tissues 
using turbulence and mechanical shearing. The disrupted sample was then 
snap frozen using liquid nitrogen. 
 
For subsequent mRNA extraction, all samples were defrosted for 5 
minutes in a water bath at 55-65oC. They were then placed into a 
centrifuge for 5 minutes at 13,000 rpm. The supernatant was carefully 
transferred into a new eppendorf, discarding any unhomogenized tissue. 
An equal volume of 70% ethanol was then added to the supernatant. The 
samples were then mixed by vortexing. 700µl of the mix was pipetted 
into the Rneasy mini column, which was placed into a collection tube. 
The column and tube were centrifuged at 9000rpm for 1 minute. The mini 
column contains a silica-gel-based membrane, which allows binding of 
total RNA whilst contaminants may be washed away. Although the 
protocol states that the follow through may be discarded, after several 
extractions with poor yield of RNA, it was discovered that it was 
beneficial to pipette the follow through back into the mini column and re-
centrifuge for a further minute before discarding.  
 
This process was then repeated for the remaining buffer/ethanol mix. 
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350µl of buffer RWI (ethanol containing) was then added to the mini 
column and the column was left to stand for 15 minutes with its lid open. 
After 15 minutes, the column was placed into the centrifuge at 9000 rpm 
for 1 minute. At this point a DNase step was performed. This step is 
optional but used for the purpose of this study as Taqman PCR analysis is 
sensitive to even small amounts of DNA. 
 
 
 
4.3.2 DNase Step 
 
A mixture of 10µl DNase stock solution and 70µl buffer RDD was made 
up, for each sample.  This was then mixed gently by inverting the tube. 
80µl was pipetted directly onto the membrane within the mini column 
and left, with lids open for 15 minutes. After 15 minutes, a further 500µl 
of buffer RWI was pipetted into the mini column and the column 
centrifuged at 8000 rpm for 1 minute. At this point the follow through 
was discarded and the mini column placed into a new collection tube. 
500 µl of RPE was then added to the mini column and centrifuged at 
9000 for 1 minute. The follow through was then discarded and a further 
500 µl RPE added, centrifuged at 9000 rpm for 3 minutes and discarded. 
The mini column was then centrifuged at 10,000 rpm for 3 minutes in 
order to dry out the membrane and then transferred into a new collection 
tube. 
80µl of RNase free water was then added directly onto the membrane and 
left to stand for 2 minutes. The mini column was then centrifuged at 
10.000 rpm for 3 minutes. A further 65µl of RNase free water was then 
added and the mixture left to stand for 5 minutes. The column was then 
centrifuged at 13000 rpm for 4 minutes. 145µl of follow through was then 
collected into two new eppendorfs; 10µl in one eppendorf for RNA 
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quantification and the remaining 135µl into another for archival storage at 
–80oC. 
 
 
4.4 RNA analysis 
 
There are many different methods of analysing and quantifying RNA. 
Usually, the quality is checked by gel electrophoresis whereby two 
distinct bands form; 28s and 18s. The ratio of 28S:18S should be at least 
2:1 thereby confirming that the RNA has not undergone significant 
digestion by RNases. If the RNA has degraded, the ratio will be reversed. 
With this method of quality control it is the ribosomal (rRNA) and not the 
messenger RNA that is checked as it is the rRNA which produces the 
strong bands. Messenger RNA only produces a faint smear on a gel. 
 
Initially the ‘Ribogreen RNA quantification’ kit was used to quantify the 
RNA. It is a fluorescent nucleic acid stain that is able to accurately 
quantify or detect as little as 5ng/ml RNA. Those samples mostly 
included normal breast tissue, which due to its high fat content tended to 
produce lower yields of mRNA. Breast tumour tissue, however produced 
much higher quantities of mRNA and so for these samples, the Agilent 
bioanalyzer was used. 
 
 
 
 
 
 
 
 
 
38 
 
4.4.1 Ribogreen RNA Quantification Kit 
 
The Ribogreen method of RNA quantification is a sensitive fluorescent 
nucleic acid stain that may be used in conjunction with a fluorescence 
microplate reader. The Ribogreen reagent is an unsymmetrical cyanine 
dye which demonstrates a >1000 fold increase in fluorescence when 
bound to RNA. Free nucleotides and contaminating proteins do not 
interfere with the measurement. It is essential that all samples have had 
DNA removed as it also binds to the Ribogreen reagent. 
 
Samples to be quantified were removed from –80oC storage and kept on 
ice. Clean disposable gloves were used throughout to minimise 
contamination from RNases. TE assay buffer was provided at 20x 
strength required. It comprised 10mM Tris-HCL and 4mM EDTA at pH 
7.5 and was diluted to 1/20 using nuclease-free water (2ml TE was added 
to 38ml water). Nuclease-free water was prepared by treatment of 
distilled de-ionised water with 0.1% diethyl pyrocarbonate (DEPC) 
followed by incubation for 2-3 hours at 37oC and then autoclaved for 15 
minutes. This sterilizes the water and eliminates the DEPC. 
 
 
 
 
4.4.1.1 Tumours and normal tissue 
 
400µl of TE was pipetted into each autoclaved eppendorf meant for 
tumour. 2µl of tumour RNA was then pipetted into the TE buffer. 300µl 
of TE was used for each sample of normal breast tissue. 5µl of normal 
RNA was then pipetted into the TE buffer. 
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The Ribogreen reagent was then made into a 1 in 200 solution by taking 
50µl of Ribogreen and 9.95ml of TE buffer and protecting from light. 
200µl of the Ribogreen solution was then added to each of the above 
tumour or normal tissue samples. 100µl of this mix was then pipetted into 
three consecutive wells within a 96 well plate and incubated for 2-5 
minutes. 
 
4.4.1.2 Standard Curve 
 
A standard curve was then prepared to display the linear correlation 
between RNA concentration and fluorescence. Ribosomal RNA was 
provided at 100µg/ml and diluted to 2µg/ml using 10µl of standard RNA 
in 490µl of TE buffer 
 
The following solutions were then prepared: 
 
Vol of 2g/ml 
RNA (l) 
Vol of TE 
(l) 
1:200 
Ribogreen 
agent 
Concentration of 
RNA (ng/ml) 
160 40 200 800 
120 80 200 600 
100 100 200 500 
80 120 200 400 
60 140 200 300 
40 160 200 200 
20 180 200 100 
10 190 200 50 
0 200 200 0 
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At each concentration, 100µl of solution was pipetted into 3 consecutive 
wells within the above mentioned 96 well plate and incubated for 2-5 
minutes. 
The 96 well plate containing the sample RNA and the standard curve was 
then placed in a fluorescence microplate reader and measured at 450-520 
nm. The instruments gain was set so that the sample containing the 
highest RNA concentration yielded fluorescence intensity near to the 
maximum. This ensured that all sample readings remained in the 
detection range. 
 
The average of all three fluorescence values was calculated for each 
sample. The fluorescence value of the blank reagent was subtracted from 
each of these values. For the standard curve graph, this resulting value 
was then plotted as a scatter graph against the RNA concentrations 
(Figure 4). From the plots on the graph a trend line was then added and 
from this the y-intercept value was calculated. 
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Figure 4. Representative standard curve of different sample 
RNA concentrations (each value is the mean of three 
fluorescence values) quantified using the Ribogreen assay 
fluorescence.   
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4.4.1.3 Calculation of RNA from standard curve 
 
The mean of three fluorescence values was calculated per sample. The 
fluorescence value of the blank reagent was then subtracted from this 
value. This value was then used to calculate the concentration of RNA 
according to the dilution factor used in making up the RNA/TE and 
ribogreen solutions. 
4.4.1.3.1 Tumour 
 
[Fluorescence/y-intercept] x [400/2] x [400/200] = concentration of RNA 
ng/ml. 
 
4.4.1.3.2 Normal tissue 
 
[Fluorescence/y-intercept] x [300/5] x [400/200] = concentration of RNA 
ng/ml. 
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4.4.2 Agilent Bioanalyzer 
 
The RNA 6000 Nano Labchip Kit simultaneously measures quantity and 
quality of messenger or total RNA (Figure 5). It comprises a lab chip and 
a bioanalyzer attached to a PC. Each sample is injected into a well and 
then moves sequentially from its well to a central separation 
microchannel, where it is separated electrophoretically. As the fragments 
move down the central separation channel, they separate by size and are 
detected by fluorescence and recorded by the bioanalyzer machine. 
 
Samples were removed from –80oC storage and placed on ice. The 
protocol recommends that all RNA samples should be heat denatured at 
70oC for 2 minutes. However due to the poor yield of RNA this practice 
was not continued. 
 
The Bioanalyzer electrodes were cleaned prior to each chip. This was 
performed by adding 350µl RNase ZAP to one of the wells of an 
electrode cleaner. This cleaner was then placed into the Agilent 2100 
bioanalyzer and left for 1 minute. It was then removed and a second 
electrode cleaner was filled with 350µl RNAse free water. This was 
placed into the Agilent 2100 bioanalyzer for 10 seconds and then 
removed. Another 10 seconds was then waited to allow the water on the 
electrodes to evaporate. 
 
The gel was prepared by pipetting 400µl of RNA 6000 Nano gel matrix 
into the top receptacle of a spin filter. The spin filter was then placed in a 
microcentifuge and spun at 4000 rpm for 10 minutes. 130l of filtered 
RNA gel matrix was added to an RNase free 1.5 ml microfuge tube and 
2l of 6000 Nano dye concentrate was then added. The tube was then 
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closed and vortexed thoroughly. The eppendorf was then centrifuged for 
10 minutes at 14 000 rpm.   
 
The chip priming station base plate was placed in position ‘C’. An RNA 
Nanochip was removed from a sealed bag and placed on the chip priming 
station. 9l of the gel dye mix was pipetted into the bottom of the well 
marked ‘G’. Care was taken to avoid bubbles. The plunger was then 
advanced to the 1ml level, the chip priming station was closed and the 
plunger pushed into place by the syringe clip. This remained in position 
for 30 seconds. After 30 seconds the plunger was pulled back to the 1ml 
position. The chip primary station was then opened and the back of the 
chip was checked for airbubbles. Commonly small bubbles will be seen 
in the wells after pipetting but the vortex procedure will commonly 
remove these bubbles. If bubbles were present in the channels of the chip 
the plunger was again pressed down and bubbles were checked for. This 
is a fairly rare occurrence but can occur if a good seal is not formed when 
the chip is pressurized the first time. The priming station was then opened 
and 9l of gel dye mix pipetted into the two wells above the one marked 
‘G’. 
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Figure 5. RNA Nano Labchip in chip priming station. Each 
chip analyses 12 samples simultaneously. G represents the 
well containing the gel-dye mix and # represents the well 
containing the ladder. 
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5l of RNA 6000 Nano marker was pipetted into the well marked 
‘ladder’ and then into each of the 12 wells consecutively. All 12 wells 
should be filled with sample buffer, even when running less than 12 
samples. None of the wells should be left empty or the chip would not run 
properly. An additional 1l of RNA 6000 Nano marker should be added 
to the 5l of sample buffer in the unused sample wells.  
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4.4.2.1 Loading the ladder and samples 
 
3µl of RNA 6000 ladder was pipetted into an autoclaved eppendorf and 
denatured at 70oC for 2 minutes. 1µl was then pipetted into the bottom of 
the well marked with a ladder sign (#). 
1µl of each sample to be analysed was pipetted into each of the 12 sample 
wells. The chip was then placed into the adapter of the vortex mixer and 
vortexed for 1 minute at set point 2400 rpm. 
 
After vortexing, the chip should be placed in the Agilent 2100 
bioanalyzer and the run should be started within 5 minutes. The chip fits 
into the receptacle one way, and should not be forced into position.  The 
lid should be closed. The software instructions on the accompanying PC 
were then followed; the correct assay selected, the sample wells labelled 
and the ‘start’ button clicked to commence the assay. All RNA 
concentrations were then collected from the PC at the end of the assay. 
 
 
4.5 Real time reverse transcriptase polymerase chain 
reaction (RT-PCR) 
 
RT-PCR is a sensitive, in vitro method used to detect messenger RNA 
(mRNA). It is used to measure the abundance of specific RNA or DNA 
sequences in clinical samples and may also be used to screen for 
mutations and single nucleotide polymorphisms. The Taqman assay has 
been used to quantify transcription from individual cells79 and paraffin 
embedded tissue80. It has wide ranging clinical applications and has been 
used to screen serum for genetic diseases81 and has been useful in the 
detection of erb-B2 transcription in breast cancer82. 
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 The technique relies on having unique, known sequences of DNA either 
side of the segment to be amplified. Short DNA oligonucleotides 
complementary to the flanking sequences are required and are known as 
primers. DNA may be heated in order to denature the double helix and 
become single strands. Upon cooling, double stranded DNA reforms. If 
an excess of oligonucleotide primers complementary to the sequences 
flanking the segment of interest are added, they will preferentially anneal 
to the segment and with the addition of a DNA polymerase enzyme, a 
second strand complementary to this segment will be produced. The DNA 
polymerase of the thermophile algae Thermus aquaticus (Taq.) is stable at 
the temperatures required to cause dissociation of double stranded 
DNA83. Use of Taq polymerase allows a rapidly repeating cycle of 
denaturation, primer annealing and sequence extension to occur and is 
known as a polymerase chain reaction (PCR). It is a process that was first 
reported in 198584 and has since been modified to incorporate Taq 
polymerase and an automated thermocycler85. The PCR reaction 
amplifies DNA. mRNA may be reverse transcribed in order to form 
complementary DNA (cDNA) using a reverse transcriptase (RT) enzyme. 
RT enzymes were originally derived from retroviruses and are now 
manufactured from cloned viral genes. Using this technique, it is possible 
to rapidly detect very small amounts of mRNA. 
 
The first step in the assay is the enzymatic conversion of RNA to a 
single-stranded cDNA template. This is followed by exponential 
amplification in a PCR reaction (Figure 6). Dedicated RNA and DNA 
dependant DNA polymerises may be used in single or separate reactions. 
This allows for the customisation of individual RT-PCR assays. 
Separation of the RT and PCR steps allows a stable library of cDNA to be 
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generated which may be stored for long periods, alternatively a single 
polymerase which acts as both an RNA and DNA-dependant DNA 
polymerase may be used in a single reaction thereby minimising error and 
risk of contamination. 
 
 
 
4.5.1 Reverse transcription 
 
Two commonly used reverse transcriptases (RTs) are avian 
myeloblastosis virus revere transcriptase (AMV-RT) and Moloney 
murine leukaemia virus reverse transcriptase (MMLV-RT). RNA 
transcripts may have significant secondary structure that affect the ability 
of the RNA-dependant DNA polymerase (RT) to generate transcripts86 
and may also affect RT-PCR quantification. AMV-RT is the most robust 
RT, retains significant polymerisation up to 55oC and may also eliminate 
any problems associated with RNA secondary structure. MMLV-RT 
however has significantly less RNAse H activity, which can interfere with 
the synthesis of long amplicons87;88. 
 
The RT step may be primed by specific primers, random hexamers or 
oligo-dT primers. Use of random hexamers and oligo-dT primers can 
maximise the number of mRNA molecules that may be analysed from a 
very small sample of RNA. mRNA specific primers were used for the 
purposes of this research however since they decrease background 
priming and use of random hexamers can overestimate mRNA copy 
numbers up to 19-fold89. 
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Figure 6. PCR reaction. The graph demonstrates product 
accumulation during the exponential and plateau phases of 
the reaction (log scale). 
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4.5.2 The Polymerase Chain Reaction 
 
A variety of thermostable DNA-dependant polymerases are available and 
differ in their processivity, thermal stability, fidelity and ability to read 
modified triphosphates such as deoxyuridine and deoxyinosine in the 
template strand90;91. 
 
The most commonly used enzyme, Tag DNA polymerase was used for 
the purpose of this research. It has an oligonucleotide which is labelled at 
one end (5’) with a fluorescent group and has a quencher at its 3’ end 
(Figure 7). It has a 5’-3’ nuclease activity but lacks a 3’-5’ proofreading 
exonuclease activity. 
 
The labelled oligonucleotide and primers were added to the PCR assay. 
When the fluorescent and quenching groups are close together, the 
emissions from the reporter dye are absorbed by the quencher dye and so 
the fluorescent emission is low. As the DNA is amplified, an increasing 
amount of oligonucleotide probe hybridises to the denatured DNA. 
During the extention phase of the PCR cycle, the 5’-3’ exonuclease 
activity of the polymerase cleaves the fluorophore from the probe. As the 
fluorophore moves away from the quencher, there is an increase in 
fluorescence. This is measured in proportion to the amount of DNA 
synthesized during the PCR. The Stratagenee Mx4000 as used in this 
study, contains photomultiplier tubes in order to detect the fluorescence. 
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4.5.3 One-enzyme RT-PCR 
 
The one enzyme system is useful where target RNA contains extensive 
secondary structure. It utilises Thermus thermophilus (Tth) polymerase 
which is a DNA polymerase with intrinsic RT but no Rnase H activity92. 
This technique is particularly useful in reducing the amount of hands-on 
time in the experimental set up and therefore minimises the potential 
contamination of reaction mixtures. A study has also shown the RT-PCR 
reactions using Tth polymerase may be more robust and resistant to 
inhibitors93. The drawbacks of this technique are that it is not as sensitive 
as the two-enzyme technique94;95, the presence of Mn2+ ions reduces the 
fidelity of nucleotide incorporation96, Tth polymerase lacks a 3’-5’ 
exonuclease proofreading activity and first strand synthesis must be 
initiated from specific rather than random primers. 
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Figure 7. Polymerase chain reaction using Taqman technology. I: 
oligo labelled with fluorescent group, II: polymerase cleaves the 
fluorophore from probe, III: probe fluoresces as DNA polymerase 
seperates fluorophore from quencher. 
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4.5.4 Instrument 
 
The Mx4000 real-time multiplex quantitative PCR system was used to 
accurately quantify mRNA. It is a fluorescence based kinetic technique 
that uses a halogen lamp in order to excite fluorescence. It also contains 
an integrated personal computer that operates independently from the 
instruments embedded microprocessor, which is useful in protecting 
against loss of data. 
 
All PCR was performed using the Mx4000 Mutiplex OPCR System. 
Samples were prepared in a 96 well microplate, which consisted of 12 
strips of 8 wells. The strips were then placed in the thermal cycler. 
Amplification and detection occur in the same tube thereby minimising 
handling of samples (‘one step’ technique). The wells are cone shaped to 
improve temperature conductivity. The light source of the Mx4000 is a 
quartz tungsten halogen lamp. It excites a wide variety of fluorophores. 
Light from the halogen lamp is directed into the 4 fibre optic illumination 
paths.   
 
Target sequences were amplified and detected in the same instrument and 
the rate of accumulation of amplified DNA was measured by the machine 
over the course of the PCR assay. The greater the concentration of target 
sequences, the fewer the number of cycles required to achieve a yield of 
amplified product. The concentration of target sequences may be 
expressed as the fractional cycle number (Ct) required to achieve a 
threshold of amplification. Ct may then be plotted against the log of the 
copy number to give a standard curve. This graph may then be used to 
quantify target sequences of unknown samples. 
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 With every PCR assay, fluorescence values are recorded during each 
cycle and represent the amount of product amplified to that point in the 
amplification reaction. The greater the RNA template at the start of the 
reaction, the fewer the number of cycles taken to reach the point in which 
the fluoresecent signal is statistically higher than the background value. 
This point is referred to as the Ct and always occurs during the 
exponential phase of amplification. 
 
The reporter signal is normalised to the fluorescence of an internal 
reference dye to allow for corrections in fluorescent fluctuations caused 
by changes in concentration or volume, and a Ct value is reported for 
each sample. The value may then be translated into a quantitative result 
by constructing a standard curve. 
 
4.5.5 Optimisation 
 
4.5.5.1 One step RT-PCR 
 
The BrilliantTM plus single-step quantitative RT-PCR core reagent kit was 
used for all RT-PCR assays. The single-step technique is useful for 
performing cDNA synthesis and PCR amplification in one tube and using 
one buffer. This permits the RT reaction to be carried out at increased 
temperatures using primers and significantly higher melting temperatures, 
while reducing both hands on time and the likelihood of introducing 
contaminants into reaction mixtures. 
The kit also includes StratascriptTM reverse transcriptase which is a novel 
Moloney murine leukaemia virus reverse transcriptase (MMLV-RT) 
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without any Rnase H activity. This mutant of MMLV-RT is able to 
produce larger yields of full length cDNA transcripts than wild type 
MMLV-RT which has substantial Rnase H activity. Rnase H has a highly 
undesirable degradative activity which can affect the reverse transcriptase 
function. 
SurestartTM Taq DNA polymerase is used as part of the single-step 
technique. It is a modification of Taq2000TM DNA polymerase with hot 
start capability. SurestartTM Taq is able to reduce background and 
increase amplification of desired PCR products. The main drawback of 
this technique is that is may not be as sensitive as two-enzyme 
technique94;95. 
 
4.5.5.2 Primers and probes 
 
 
The primers and probes used in this study included IGF-1, IGF-1R, 
IGFBP-3, GH, GHR, ghrelin, ghrelin 1B receptor, somatostatin, 
somatostatin receptor 5, c-myc, cycloxygenase-2 (COX-2), PCNA, 
vascular endothelial growth factor (VEGF 165 and 189), 1 alpha 
hydroxylase, Vitamin D receptor and HTERT. They were newly designed 
using Primer Express software and are shown in Table 1. 
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Table 1. Table of primer and probe sequences. Forward and reverse 
primers and Taqman probes (sequence 5’-3’) used in RT-PCR. 
 
 
Gen
es 
Forward Primer Reverse Primer  Taqman probe 
IGF-
1 
CTTCAGTTCGTGTGTGGAG
ACAG 
CGCCCTCCGAC
TGCTG 
TTTTATTTCAACAAGC
CCACAGGGTATGGC 
IGF-
1R 
CTCCTGTTTCTCTCCGCCG  ATAGTCGTTGC
GGATGTC GAT 
TGGCCCGCAGATTTC 
TCCACTCGT 
IGF-
BP3 
AGCACAGATACCCAGAACT
TCTCC 
TCCATTTCTCT
ACGGCAGGG 
CATATTCTGTCTCCCG
CTTGGACTCGG 
GH CCC TCCAACAGG GAGGAAA  CGACTGGATGAG
CAGCAG G  
AGAAATCCAACC TAG 
AGCTGCTCCGCATCT 
GHR TTTGGAATATTTGG 
GCTAACAGTG         
TCACCTCCTCTAA
TTTTC CTTCCTT      
AAGGATTAAAATGCT 
GATTCTGCCCCCAGT 
Ghrel
in 
GGGCAGAGGATGAACTGGAA CCTGGCTGTGCTG
CTGGTA 
TCCGGTTCAACGCCCCCT
TTG 
Ghrel
i 1B 
rec 
TCGTGGGTGCCTCGCT GCTGAGACCCACC
CAGCA 
AGGGACCAGAACCACAA
GCAAACCG 
Soma
tostat
in 
TCGCTGCTGCCTGAGGACCT GCCAAGAAGTAC
TTGGCCAGTTC 
AACTGATTTCATCGGAAG
CACCGG 
Soma
tRec5 
GCCGGCCTCTACTTCTTCGTG CCGTGGCGTCAGC
GTCCTTGG 
CCGTCCTCTCAGGCTTCCT
CTCGGA 
cMyc TGAGGAGACACCGCCCAC CAACATCGATTTC 
 
TTCCTCATCTTC 
CCAGCAGCGACTCTGAGG
AGGAACA 
Cox-
2 
GAATCATTCACCAGGCAAATTG TTTCTGTACTGCG
G GTGG AAC 
TTCCTA CCACCAGCA 
ACCCTGCCA 
PCN
A 
TTAAATTGTCACAGA 
CAAGTAATGTCG 
TGGCTTTTGTAAA
GAAGT 
TCAGGTAC 
TGGTTCATTCATCTCTAT 
GGTAACAGCTTCCTC CT 
VEG
F-
165 
TGTGAATGCAGACAAAGAAAGA GCTTTCTCCGCTC
TGAGCAA 
AGAGCAAGACAAGAAAA
TCCCTGTGGGC 
VEG
F-
189 
TGTGAATGCAGACCAAAGAAAG
A 
CGTTTTTGCCCCT
TTCCC 
AGAGCAAGACAAGAAAA
TCCCTGTGGGC 
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1 
hydro
x 
GCTATTGGCGGGAGTGGAC GCCGGGAGAGCT
CATACAGA 
CCCAAGAGAGCGTGTTGG
ACACCG 
Vit D 
recep 
ATCTGCATCGTCTCCCCAGAT 
 
AGCGGATGTACGT
CTGCAGTG 
TGATTGAGGCCATCCAGG
ACCGC 
htert AGTTGCAAAGCATTGGA 
 
ACCTCTGCTTCCG
ACAGC 
AGCTGCACCCTCTTCAAG
TGCTGTCTGA 
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Taqman probes are linear with the fluorophore at the 5’ end and the 
quencher either at the 3’ end or internal. If the probe is intact, no 
fluorescence is emitted from the fluorophore. During the annealing phase, 
the primer and probe hybridise with the target. The DNA polymerase then 
displaces the probe and the 5’ nuclease activity of the DNA polymerase 
separates the fluorophore from the quencher. During each PCR cycle, 
fluorescence may then be detected as it accumulates. The probes should 
have a melting temperature of 7-10oC higher than that of the primers. The 
ideal concentration should be determined empirically, ideally being the 
lowest concentration, which results in the lowest Ct with an adequate 
fluorescence. 
 
Probe concentration is usually in the 100nM range and they must compete 
for binding to their target with the amplification primers, which are 
present in greater concentrations. As amplification primers are extended 
as soon as they bind to their targets, the hybridisation target sequence is 
rapidly masked with newly synthesised DNA.  Therefore the melting 
temperature (Tm) of the probe must be significantly greater 
(approximately 10o C) than that of primers, to ensure that they hybridise 
before the primers.  Most probes used here were approximately 30 bases 
in length with a G/C content of approximately 50%. This ensures good 
specificity and a Tm high enough to be useful under PCR conditions. 
 
Primers should bind to separate exons to avoid false positive results 
arising from amplification of contaminating genomic DNA. RNAse-free 
DNase was used in the purification of RNA preparations, as the 
intron/extron boundaries were unknown. Primer selection is based on 
estimated melting temperatures (Tm), the desire for small amplicon size 
and location of the probe. They must be designed to exact specifications 
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and the Taqman technology provides its own primer and probe design 
programme known as Primer Express. 
 
The optimal concentration of upstream and downstream primers is also 
the lowest concentration which results in the lowest Ct with an adequate 
fluorescence. When used with Taqman probe, the primer concentration 
may be varied between 50 to 300 nM and should be determined 
empirically. Too great a primer concentration may result in mispriming 
and accumulation of non-specific product. Too low a primer 
concentration is less problematic for real-time assays as target copy 
numbers will have been calculated well before the primer supply is used 
up. 
 
The optimal length for single stranded primers is approximately 15-20 
bases, the G/C content should be between 20-70% and their Tm should 
not differ by more than 1-20C. The minimum Tm should be 580C and the 
maximum should be 600C. PCR primers were designed with similar 
annealing temperatures for all targets to be amplified. 
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4.5.5.3 Magnesium chloride 
 
Magnesium chloride concentration requires strict control as it can affect 
the specificity of the PCR primers and probe hybridisation. The ideal 
concentration is that which results in the lowest Ct and the highest 
fluorescence at a given target concentration. The MgCl2 concentration 
may be titrated from 2-6mM with increments of 0.5mM; in these 
experiments, MgCl2 concentration of 3mM was found to be optimal. 
 
In addition, MgCl2 can increase the melting temperature (Tm) of double 
stranded DNA and forms soluble complexes with dNTPs which can 
produce the actual substrate that the polymerase recognises. High 
concentrations of dNTPs therefore interfere with polymerase activity and 
affect primer annealing by reducing free MgCl2. 
 
 
4.5.5.4 Internal reference dye 
 
A passive reference dye was used to provide a stable baseline to which 
the samples were normalised. The dye provided was diluted to 1:200 and 
a fresh solution was made up for each assay. 
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4.5.6 PCR Reaction and conditions 
 
The BrillantTM plus single-step quantitative RT-PCR core reagent kit was 
taken from storage at -800C and defrosted on ice. The reference dye was 
diluted to a solution of 1:200 with DEPC water. Each experimental 
reaction was made up to a volume of 25µl per sample. Each reaction was 
performed in duplicate, therefore the final volume per sample was 50µl. 
 
The following reagents were then pipetted, in order, into an autoclaved 
eppendorf. A master mix for all samples was made up at the beginning of 
an experiment to reduce pipetting error. 
2.5µl of 10x core RT-PCR buffer 
1.5µl of 50nM magnesium chloride 
2µl of dNTP mix 
1.25µl of primer mix (forward and reverse) 
0.25µl of StrataScript RT poymerase 
0.25µl of SureStart Taq DNA polymerase 
0.38µl of diluted reference dye 
0.5µl of probe 
2µl of RNA template 
14.37µl of nuclease-free DEPC water to make solution up to a final 
volume of 25µl 
 
This solution was then placed in the centrifuge at 13,000 rpm for 2 
minutes. 46µl of the mix was then pipetted into each individual 
microcentrifuge tube and 4µl of experimental RNA was added. For each 
assay 2 positive controls (liver RNA), 2 negative controls (water) and 
approximately 6 amplicons (serially diluted) were run in parallel. 
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 Pipetting up and down then mixed each one and the pipette tip was 
discarded each time. The microcentrifuge tubes were then placed in the 
centrifuge for 3 minutes at 300 rpm. 25µl of each experimental reaction 
was then aliquotted into duplicate microcentrifuge tubes. The optics caps 
were then carefully and firmly positioned onto the microcentrifuge tubes. 
The tubes were then placed into the centrifuge for a further 3 minutes at 
300 rpm. 
 
Taking care not to disturb the samples, the microfuge tubes were then 
transferred into the thermal plate. The reaction and thermal profile were 
then set up using the software package on the connecting PC. The thermal 
profile used for each PCR reaction in shown below (Figure 8). 
 
The data was collected at each ‘END’ point. Using the software, it was 
possible to determine the Ct values for each sample performed in 
duplicate. 
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Figure 8. Thermal reaction conditions for each PCR 
reaction. Stages 1 and 2 =RT, stage 3=PCR (45 cycles). 
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4.5.7 Quantification 
 
Quantification of mRNA may be performed by quantitative or semi-
quantitative methods97. Commonly, semi-quantitative methods are 
employed by sampling the RT-PCR reaction mixture and dot-blot 
analysis98 which are not precise and laborious. Quantitative techniques 
may be competitive or non-competitive99;100. 
 
Non-competitive RT-PCR involves the co-amplification of the target with 
a second RNA molecule under reagent concentrations and conditions so 
that there is no competition between target and standard101. In these 
circumstances, quantification may be unreliable as the efficiencies of the 
RT and PCR steps may vary. Competitive quantification involves spiking 
into the RNA samples before RT of known amounts of RT-PCR 
amplifiable competitors that should be synthetic RNA molecules. The 
internal standard shares the same primer recognition and internal 
sequences as the primary target and so competes for reagents. Both 
should be amplified with the same efficiency as they are virtually 
identical and their amplicons may be distinguished by the addition of a 
restriction enzyme site to the standard102 or by varying its size103. A series 
of PCR tubes containing the target are spiked with serial dilutions of 
known copy numbers (107, 106, 105 etc) of the internal standard. The 
higher the concentration of the internal standard, the more likely the 
primers will bind and amplify it rather than the target. Gel electrophoresis 
may therefore be performed and a comparison can be made of ethidium 
bromide stained standard and target amplicons to allow target 
quantification104. There is still however, approximately 10% error and this 
method may still not result in absolute quantification as differences in 
amplification efficiency between target and competitor will remain 
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undetected. 
 
4.5.7.1 Normalisation 
 
It is well established that an appropriate standard needs to be used within 
each PCR experimental assay. The accepted method is to amplify a 
cellular RNA at the same time as the target, which serves as an internal 
reference against which other RNA may be normalised105. The ideal 
standard should be expressed at a constant level among different tissues, 
at all stages of development and should be unaffected by experimental 
treatment106. The problem with this method is that errors easily occur in 
the amount of starting material between samples. There may also be 
differences in the amount of RNA obtained from different tissue types e.g 
normal and malignant tissue, and differences also exist when samples 
have been taken from different patients. Therefore, obtaining an ideal 
standard that accommodates these differences is an important part of the 
assay.  
 
Three commonly used RNAs to normalise gene expression include the 
mRNAs specifying the housekeeping genes glycerldehyde-3-phosphate-
dehydrogenase (GAPDH), β-actin and ribosomal RNAs  (rRNA). 
GAPDH is ubiquitously expressed by most tissues and its expression has 
been shown to be constant at different times throughout experimental 
manipulation107;108. Evidence does suggest however that GAPDH 
concentrations vary greatly amongst individuals109, during pregnancy110, 
with developmental stage111;112 and during cell cycle113. It has also been 
shown to be up regulated in tumours and this variation therefore suggests 
that its use as a normal control may be inappropriate. 
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β-actin is also moderately expressed in most cell types. It is traditionally 
used as an internal standard in PCR assays. Several studies however have 
shown that transcription levels may vary widely in breast epithelium cell 
culture studies114. rRNA constitutes 85-90% of total cellular RNA are  
generated by a distinct polymerase115 and their levels are less likely to 
vary under conditions that affect the expression of mRNAs116. rRNA 
transcription can however be affected by biological factors, drugs and 
may vary amongst individuals114. It is also expressed at much higher 
levels than target mRNAs and cannot be used for normalisation when 
targets have been enriched for mRNA as it is lost during mRNA 
purification. 
 
There are obviously inherent problems associated with normalising to an 
internal standard and with comparing copy numbers between samples 
obtained from different individuals or tissues. In this study we normalised 
copy numbers relative to total RNA concentration. Little is known 
however about the total RNA content per cell of different tissues in vivo 
or how this may vary between individuals and between normal and 
malignant tissue. Bustin et al addressed some of these issues by obtaining 
blood from healthy patients and counting and purifying nucleated blood 
cells. RNA content was quantitated and little variation was observed in 
amount of total RNA per cell thereby confirming the validity of this 
technique in comparing results between individuals117. 
 
RNA concentration was determined accurately using the Agilent 
Bioanalyzer and also confirmed using Ribogreen quantification as 
described earlier. Copy numbers of target genes were then recorded as 
copy numbers per µg total RNA. The drawbacks of this approach include 
the fact that total RNA may be increased in highly proliferating cells and 
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so this may affect the accuracy of comparing absolute copy numbers 
between normal and malignant tissue106. In order to compare our 
normalisation technique with the standard housekeeping gene method, 
GAPDH mRNA expression was measured on all samples according to the 
PCR protocol. 
 
 
4.5.7.2 Generation of standard curves 
 
Standard curves were constructed with each experimental reaction in 
order to determine the absolute quantification of mRNA transcription. 
This method allows the copy number per cell to be determined. A 
standard curve was constructed for each amplicon thereby ensuring 
accurate reverse transcription and PCR amplification profiles (99). The 
amplicons were diluted serially as follows; 10 -10, 10 -9, 10 -8, 10 -7, 106, 
105, 104, 103, 102 and 101 using TE buffer. These samples were then run 
alongside each RT-PCR assay and the Ct values obtained were used to 
construct an absolute standard curve. A linear graph was obtained from 
three independent serial dilutions of amplicon and assaying each dilution 
in duplicate, together with positive and negative controls. This allows the 
copy number per cell to be determined from absorbance. The dilutions 
were made over the range of copy numbers expected from the target 
mRNA expected in the experimental samples in order to maximise 
accuracy. 
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4.6 Immunohistochemistry 
 
4.6.1 Introduction to immunohistochemistry 
 
Immunohistochemistry allows the identification and localisation of 
proteins on tissue sections using antibodies linked to enzymes that 
produce colour changes in indicator dyes. This involves the binding of a 
primary antibody to the antigen and secondly, the detection and 
visualistion of the bound antibody by one of a variety of enzyme based 
chromogenic systems. The type of chromogenic substrate depends in the 
type of enzyme used e.g aminoethyl carbazole (AEC) and 
diaminobenzidine (DAB) may be used with horseradish peroxidise. DAB 
substrate has a high sensitivity and produces an insoluble, permanent 
brown precipitate which has a high contrast in photographs. 
Amplification of the staining may be achieved by using antibodies and 
enzymes which combine through binding proteins such as the avidin 
biotin system. This system essentially involves three steps; primary 
antibody, biotin-labelled secondary antibody and avidin-biotin-peroxidise 
complex. A lattice-like complex is therefore produced which is attracted 
to the site of biotin-labelled antibody to give sensitive staining118. 
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4.6.2 Tissue and its preparation 
 
4.6.2.1 Sample preparation 
 
Immunohistochemistry against IGF-1 was performed on 3l sections of 
paraffin embedded blocks of 24 randomly selected paired samples of 
breast tumour and adjacent normal tissue, which had previously 
undergone RNA analysis. The avidin biotin complex (ABC) 
immunohistochemistry method was used119. 
 
4.6.3 Protocol for DAB staining 
 
Tissues were prepared using standard fixation and paraffin embedding 
techniques courtesy of the Pathology Department, St Bartholomew’s 
Hospital. Paraffin sections were then dewaxed and rehydrated according 
to the following standard procedures. Novozymes GroPep’s IGF-1 
Antiserum (PABCa) was used for IGF-1 detection in paraffin sections.  
For each specimen, one slide was stained as per protocol and one was 
used as a negative control and so was treated with just horse serum and 
no antibody. Sections of paraffin embedded human liver were used as a 
positive control. 
 
4.6.3.1 Standard dewaxing procedure 
 
The slides were placed into a metal rack and then placed into a glass jar 
containing xylene for 5 minutes. The rack was then placed into a second 
container of xylene for another 5 minutes to dewax. The samples were 
then rinsed in 100% absolute alcohol (BDS) for 3 minutes, then in 
separate containers of 100% alcohol for 3 minutes, 90% alcohol for 3 
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minutes and 70% alcohol for 3 minutes. The slides were not allowed to 
dry between any of the steps.  
 
100ml of 10x citrate buffer was added to 900ml of distilled water. This 
citrate buffer was then added to a microwave dish and its pH was made 
sure to be 6.0. HCL or NaOH was added if needed to make the pH=6.0. 
 
 
4.6.3.2 Antigen retrieval 
 
After the dewaxing procedure, slides were placed into a glass jar 
containing 3% H2O2 in methanol (30 mls of 3% H2O2 in 270ml of 
methanol) for 10 minutes. The 100ml citrate buffer was placed in the 
microwave for 12 minutes to heat up. Slides were then moved into a 
plastic rack, as the metal rack cannot go into the microwave. The plastic 
rack was rinsed in water and then placed into the hot citrate buffer. The 
microwavable container was then closed and heated in the microwave for 
4 minutes.  
 
Once finished the container was removed and the plastic rack of slides 
was placed under running water. Water was poured into a metal tray. 
Each slide was taken from the rack, excess water was drained off by 
blotting with paper taking care not to disturb the tissue section. The 
margins of the tissue section were then marked using an Immedge pen to 
aid viewing of the small section. Horse serum was defrosted under 
running water.  The slide was then placed on the tray and the tissue 
section covered in horse serum, taking care to use enough volume to 
completely cover the section. The tray was then left for 5 minutes at room 
temperature. 
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4.6.3.3 Primary antibody incubation 
 
Novozymes GroPeo’s IGF-1 Antiserum, affinity purified for 
Immunohistochemistry (Product code PABca) was made up in solution of 
1 in 50 using phosphate buffer saline (PBS): 12µl antibody plus 600µl 
PBS. This antibody was added only to positive slides and left out for the 
control slides. 200µl of antibody was used for big tissue sections like 
breast samples and 100µl for smaller sections such as the liver samples. 
The horse serum was then removed from the positive samples and a good 
covering of primary antibody was added. The lid was placed on the metal 
try to provide a humidified atmosphere. The tray was then placed in the 
incubator at 420C for 1.5 hours. 
 
 
 
4.6.3.4 Secondary antibody incubation 
 
The secondary antibody solution was made up of 2.35ml of PBS, 150ml 
of horse serum (3 drops) and 50ml of secondary antibody, biotinylated 
anti-rabbit IgG antibody (1 drop), all using Vectastain kit (ABC kit). This 
mixture was vortexed and then placed in the fridge. 
 
The tray was then removed from the fridge. The slides were placed back 
into the rack and then into a glass jar containing PBS for 2 x 5 minutes to 
wash off excess antibody. Excess PBS was blotted off the slide using 
tissue paper, taking care to avoid tissue section. The slides were then 
placed back onto the metal tray, the edges dried and each tissue section 
was covered fully with the secondary antibody solution. The lid was then 
placed onto the tray and incubated at room temperature for 30 minutes. 
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4.6.3.5 Tertiary antibody incubation 
 
The tertiary complex consisted of HRP-avidin and biotin complex which 
binds to the secondary antibody. The solution was prepared at least 30 
minutes before use. 
 
To prepare the tertiary antibody 2.5ml of PBS, 1 drop of A (avidin) and 1 
drop of B (biotin) was added. They were then vortexed quickly and 
placed in the fridge.  
 
DAB was made using 2.25ml water, 250ml of substrate buffer, 2 drops of 
liquid DAB and 1 drop of H202. This mixture was then labelled, placed in 
the fridge and protected from light. The slides were then taken out of the 
tray and washed twice in PBS for 5 minutes. The slides were then taken 
out of the wash and dried around the tissue sections. Tertiary antibody 
was then added and the slides were left at room temperature for 20 
minutes in the tray.  
 
After incubation with the tertiary antibody the slides were washed twice 
with PBS. The slides were then taken out of PBS and covered with DAB 
to the sections. The DAB was left for 5 minutes, and as soon as the brown 
colour was seen developing the slides were washed in water.  
 
Each DAB slide was then counterstained by rinsing with Gills 
haematoxylin for 30 seconds, followed by 1% acid-alcohol for 1 second. 
Slides were then rinsed under running water for 2 minutes, 70% alcohol 
for 2 minutes, 90% alcohol for 2 minutes, absolute 100% alcohol for 2 
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minutes, in another absolute alcohol 100% for 2 minutes, in xylene for 2 
minutes and then another xylene for 2 minutes.  
 
The cover-ups were set up by adding Depex mounting medium (Gerr) –to 
DAB slides. The cover slides were then placed onto the slides and left to 
dry overnight, and viewed under the microscope the next day. 
 
Sections of liver were used as a positive control in each run. The sections 
of normal breast and cancer were randomly mixed prior to staining. 
 
4.6.4 Quantification of Immunohistochemical Staining 
 
Sections of normal and malignant breast tissue were randomly mixed 
prior to staining. Assessment was performed in a blinded manner on two 
separate occasions by a single investigator. In order to quantify IGF-1 
protein expression, a scoring system based on the proportion of positive 
cells and intensity of staining was employed. This was scored as follows 
and a separate score determined for stromal and epithelial staining: 
 
Proportion of positive staining cells: 
 
Number of cells Score 
<5% 1 
5-50% 2 
>50% 3 
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Intensity of staining of positive cells: 
 
Intensity Score 
0 (none) 1  
+ (weak) 2  
++(moderate) 3  
+++(strong) 4  
 
 
The two scores were added together to give a score out of 7. Separate 
scores were calculated for epithelial and stromal staining. A score of 1-3 
was classified as negative and a score of 4-7 was positive. These two 
scores were combined together to give a total score out of 14: 1-
6=negative and 7-14=positive with a subgroup of 10-14= strongly 
positive. The procedure was repeated again without viewing the first set 
of results, with the mean of both readings used as a final score. 
 
 
 
 
4.7 Serum IGF-1 and IGFBP-3 
 
4.7.1 Sample collection 
 
5ml of blood was venesected from each patient undergoing breast cancer 
surgery involved in the study. Blood was taken from 36 patients on the 
day prior to breast surgery (pre-operative) and from 35 patients up to 6 
months after surgery (post-operative). These samples were not paired. Of 
the post-operative group patients were classified into those taking 
Tamoxifen (T) and those not taking Tamoxifen (NT). 
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 The blood was collected aseptically into glass tubes containing no 
additives and care was taken to avoid needlestick injury. All samples 
were centrifuged at 10,000rpm for 15 minutes at room temperature. 
Serum was separated from red cells by pipetting and collecting in a fresh 
round bottom eppendorf. These samples were frozen at –800C. 
 
4.7.2 Serum IGF-1 
 
This was measured on all samples by an in-house radioimmunoassay after 
formic acid-acetone extraction, courtesy of the Growth Factor Lab, St 
Bartholomew’s Hospital120. Total IGF-1 was measured after the samples 
were separated from their binding proteins by acetone extraction. The 
mean intra- and inter- assay coefficient of variation were 2.7% and 
10.4%, respectively. The assay sensitivity was 45ng/ml. 
 
 
4.7.3 Serum IGFBP-3 
 
Serum IGFBP-3 was measured using active IGFBP-3 enzyme-labeled 
immunosorbent assay (ELISA Kit; Diagnostic Systems Laboratories, Inc. 
Webster, Tx, USA). The mean intra- and inter- assay coefficients of 
variation were 7.2% and 10.2% respectively. The assay sensitivity was 
0.04 ng/ml. All samples and reagents were brought to room temperature 
before the assay. Serum samples were thoroughly mixed prior to use and 
diluted to 1:100 in the standard dilutent containing 0ng/ml IGFBP-3 (in a 
protein based buffer). Wells to be used were then marked on the 
microtitration strips, all samples were performed in duplicate. 25µl of 
each standard (2,5,20,50 and 100 ng/ml IGFBP-3), control (samples of 
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high and low concentration IGFBP-3) and the unknown diluted samples 
were pipetted into each well. 50µl of assay buffer was then added to each 
well. The wells were then placed in a microplate shaker at approximately 
700 rpm for 2 hours (room temperature). Each well was then aspirated 
and washed five times with wash solution. The microplate was then 
inverted and blotted dry on absorbant material. 
 
The conjugate solution was then prepared by diluting the antibody-
enzyme conjugate concentrate at a ratio of 1:50 using the assay buffer. 
100µl of this solution was then added to each well. The microplate was 
then shaken again at 700 rpm for 1 hour at room temperature. Each well 
was then washed and aspirated a further five times followed by inverting 
the plate and blotting dry. 
 
100µl of tetramethylbenzidine (TMB) solution was then added to each 
well and the plate then re-shaken at 700 rpm for 10 minutes at room 
temperature. 100µl of stopping solution (0.2M sulphuric acid) was then 
added to each well. The micropate was then placed in a microplate reader 
and absorbance measured at 450nm (background absorbance was set to 
600nm). 
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4.8 In vitro tissue explant culture 
 
4.8.1 Tissue collection 
 
Fresh breast tissue samples were obtained from breast cancer patients 
undergoing surgery. As before, fully informed consent was obtained 
(Appendix A). All cancers were clinically palpable (>1-2cm in size). 
 
 
4.8.2 Tissue processing 
 
Each breast specimen was transported from surgery to the Department of 
Pathology immediately after removal from the body. The specimen was 
orientated, inked and a sample of tumour (T) and adjacent normal tissue 
(AN) was excised by the pathologist. AN was macroscopically normal 
tissue taken as far away from the tumour as possible. Care was taken 
when dissecting normal tissue to obtain glandular tissue and avoid fat. 
Each sample was then placed into separate sterile cryogenic vials 
containing serum-free Dulbecco’s Modified Eagle’s Medium (DMEM) 
and transported quickly to the laboratory. 
 
 
4.8.2.1 Preparation of the medium 
 
The stock solution used for all experiments contained 500ml DMEM, 1g 
of bovine serum albumin, 5ml of penicillin/streptomycin mix (10mg/ml) 
and 0.5ml of amphotericin (0.25µg/ml). All were added to the medium 
via a sterile filter and stored at +40C. In order to carry out this culture 
technique, large tumours were necessary to provide enough tissue. The 
size of the specimen therefore was a limiting factor. The samples of 
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normal and malignant breast tissue were then cut into 6 small pieces (~5-
10 mg) under sterile conditions. One sample was retained as 0hrs sample. 
The remaining 5 pieces were placed in the wells of a 24 well plate. 100µl 
of stock solution was added to each well. They were then incubated at 
370C in an incubator with 5% carbon dioxide. A sample was removed 
after 6hrs, 18hrs, 24hrs, 48hrs and 72hrs and immediately frozen for 
subsequent analysis at a later date using the LDH and MTS assays. 
 
4.8.2 2 MTS Cell proliferation assay 
 
The MTS Cell Proliferation Assay was used to assess viability of the 
tissue explant technique. The assay uses mitochondrial respiration as an 
indicator of cell viability. It is based on the reduction of the MTS reagent 
(a tetrazolium salt) to form an insoluble dark blue formazen product with 
the emission of light at 490nm, by active mitochondria with 
NADPH/NADH. This bioreduction results in a coloured product soluble 
in tissue culture medium.  
 
A solution of 5mg/ml MTS dissolved in PBS was made up and filter 
sterilised. 100µl of MTS dye was added to the tissue after incubation in 
500µl media. All experiments were carried out in duplicate in a 24 well 
plate. The plate was then incubated in a CO2 incubator at 370C for 4 
hours. After 4 hours, 100µl of the media/dye mix was taken from the 
sample and control wells and an absorbance reading at 490nM 
wavelength was performed. 
 
For each time frame there was a corresponding well with medium only + 
explant and dye. This positive control was subject to the same conditions 
as the other experimental wells and was assayed with MTS in the same 
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way. Triton-X results in maximum disruption of plasma membranes and 
was used as a negative control. To make up a solution of 2% Triton, 
200µl of triton 100 was added to 9.8ml medium and mixed thoroughly. 
500µl of this solution was then added to a well containing an explant and 
incubated as protocol. 
 
In order to assess the effect of the different tissue weights on the MTS 
absorbance, normal and malignant breast tissue was dissected into 
approximately 20 explants of visibly different sizes. These explants were 
placed into a 24 well plate. MTS dye and medium were added to each 
sample well including 2 control wells. After 4 hours of incubation at 370C 
5% CO2, the plate was removed from incubation. The tissue samples 
were removed, blotted dry using absorbant paper and weighed. The 
absorbances were read and MTS values adjusted according to their 
weights. Results were obtained as absorbance minus that of negative 
control (media only). 
 
 
 
4.8.2.3 LDH Cytoxicity detection 
 
The lactate dehydrogenase (LDH) assay is another colorimetric method, 
which is used to evaluate cell death. It is based on the measurement of 
cytoplasmic enzyme activity that is released by damaged cells into cell 
culture medium upon damage to cellular plasma membranes. In contrast 
to the MTS assay, which measures metabolic activity, this assay 
quantitates cell death and lysis. The amount of enzyme activity detected 
in the culture medium correlates to the proportion of lysed or dead 
cells121. 
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 A two-step enzymatic reaction occurs when LDH containing tissue free 
media is incubated with the reaction mixture provided in the kit. The first 
reaction involves reduction of NAD+ to NADH/H+ by LDH catalysed 
conversion of lactate to pyruvate. In the second step, a catalyst from the 
reaction mixture transfers H/H+ from NADH/H+ to tetrazolium salt INT. 
This transfer results in the reduction of INT (yellow) to formazoan (red). 
The amount of red colour produced therefore correlates with the amount 
of formazoan formed and hence the amount of dead/ membrane damaged 
cells in the medium. Absorbance may then be read 
spectrophotometrically. 
 
100µl of assay medium was added into duplicate wells of a 96 well plate. 
The reaction mixture was prepared immediately prior to the assay: by 
mixing 250µl of bottle 1 (catalyst) with 11.25ml of bottle 2 (INT dye 
solution). After mixing thoroughly, 100µl of reaction mixture was added 
to each well and incubated for 30 minutes at 20-250C. The plate was 
protected from light during this time. The 96 well plate was then placed 
into a microplate reader and the absorbance read at 490nm. 
 
A negative control of medium only was used for each time point. A 
positive control of 2% Triton added to an explants was also used for each 
time frame. Triton was used to ensure maximum LDH release for the 
purposes of a positive control. 
 
In order to assess the inter-assay variability of the LDH assay, duplicate 
sets of samples were used, where tissue availability allowed. Also intra-
assay variability was assessed by assaying each well 12 times. 
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4.9 Affymetrix Chips Protocol 
 
We have demonstrated that IGF-1 is expressed in both normal and 
malignant breast tissue, but that approximately 10% of primary breast 
cancers reveal no IGF-1 mRNA expression. However the molecular 
difference between IGF-1 positive and IGF-1 negative tumours is 
unknown. To investigate the molecular differences between IGF-1 
positive and IGF-1 negative breast cancers cRNA microarray analysis 
was used. The IGF-1 expression status of 76 primary breast cancers was 
identified using real-time RT-PCR (‘Taqman’). Two IGF-1 positive and 
two IGF-1 negative breast tumours were subsequently randomly selected 
and cRNA microarray analysis was performed using the Affymetrix 
U133A Chip protocol. The resultant data was analysed using Gene Spring 
6.0 expression analysis software. 
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A flow diagram of the steps involved is: 
 
 
   total RNA 
~4 hours 
 
                               ds-cDNA 
~6 hours 
 
                                 cRNA 
~1 hour 
 
                        Fragmented cRNA 
~1 hour 
 
                            Hybridisation 
~16 hours 
 
                           Wash & Staining 
~2 hours 
 
                                  Scan 
~1 hour 
                                Analysis 
 
                       ~ 4 working days 
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4.9.1 First strand cDNA synthesis 
 
RNase free microtube tubes and pipette tips were used throughout this 
experiment. We started with 5-10µg total RNA per sample. 
The following were placed in a microfuge tube on ice: 
 
  5-10 µg total RNA     5-10µl 
 T7-(T)24 primer (100pmol/µl) HPLC purified    1µl 
 DEPC dH2O      0-5µl  
 Final volume       11µl 
 
This mixture was pipetted and spun briefly as necessary. It was then 
incubated at 65-700C for 10 minutes. The tubes were then placed on ice, 
and a master mix was made up on ice: 
 
 (5x) First Strand Buffer (thraw at 370C, put on ice) 4µl 
 DTT (0.1M)       2µl 
 DNTPs (10mM each)     1µl 
 Final volume      7µl 
 
 
This was mixed by pipetting and spun briefly as necessary. 7µl of master 
mix was added to each reaction tube, and then incubated at 420C for 2 
minutes. Superscript II reverse transcriptase (200U/µl) was added (1µl for 
5µg of total RNA or 2µl for 10µg) making a final volume of 20µl. The 
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tube was tapped to mix and spun briefly as necessary. It was then 
incubated at 420C for 1 hour in a waterbath then placed on ice before 
proceeding to “Second strand cDNA sythesis”. 
 
4.9.2 Second strand cDNA sythesis 
 
All the reagents and first strand reaction tubes were placed on ice. The 
master mix was assembled in a new microfuge tube on ice: 
 
DEPC treated dH2O    91µl 
(5x) Second Strand Buffer   30µl 
dNTPs (10mM each)     3µl 
E. Coli DNA Ligase (10U/µl)    1µl 
E. Coli DNA Pol I (10U/µl)    4µl 
E. Coli Rnase |H (2U/µl)      1µl 
 
Final volume     130µl 
 
The mixture was mixed by vortexing and then spun as briefly as 
necessary. 130µl of this master mix was added to each of the first strand 
reaction tubes (150µl final volume). This was mixed with pipetting and 
spun briefly. It was then incubated at 160C for 2 hours in a water bath in a 
cold room. This reduces condensation. 2µl (10U) T4 DNA Polymerase 
was added. It was then incubated for 5 minutes at 160C. 10µl 0.5M EDTA 
pH 8.0 was then added, causing the final volume to be 162µl. The tube 
was placed on ice and proceeded to “Clean-up of double stranded 
cDNA”. 
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4.9.3 Clean-up of double stranded cDNA 
 
This method used Phase-Lock tubes, which contained a gel that acts to 
separate the aqueous and organic layers in the phenol extraction 
permitting more complete recovery of the aqueous phase. The Phase-
Lock tube was spun in a microfuge at maximum for 30 seconds to allow 
the gel to settle to the bottom of the tube. To the sDNA reaction, an equal 
volume (approximately 162µl) of at room temperature buffer saturated 
phenol was added. This was made by adding 65µl of Alkaline Buffer 
(10mM Tris HCL pH 8.0, 1mM EDTA) to 1ml of phenol-chloroform-
isoamyl alcohol 25:24;1 (AMBION 9732). It was then vortexed for 2 
minutes and spun. The mixture was placed into a Phase-Lock tube and 
not vortexed again. It was spun at maximum in a microfuge for 2 minutes. 
The upper (aqueous) phase was transfered to a new tube, and to this was 
added: 
 
0.5 x volume NH40Ac (7.5M)    75µl 
Glycogen (5mg/ml)      4µl 
2.5 x volumes Ethanol (100%)    375µl 
 
 
The solution was mixed by tapping the tube. It was then spun at 
maximum at room temperature in a microfuge for 20 minutes. The 
supernatant was decanted being careful not to displace the pellet. The 
pellet was washed twice with 500µl (80%) cold ethanol, then spun at 
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maximum for 5 minutes. All the ethanol was removed with a pipette (it 
was spun again briefly to collect any residual ethanol on the sides of the 
tube and ethanol was removed a second time using a pipette). The pellet 
was allowed to air dry for 5-10 minutes, then resuspended in 12µl of 
DEPC treated H2O, before proceeding to the in vitro transcription 
reaction. 
 
 
 
 
4.9.4 Synthesis of cRNA (IVT reaction & labelling) 
 
All the reagents and double stranded cDNA were thawed at room 
temperature. The following reaction was assembled at room temperature: 
 
Ds-cDNA      12µl 
DEPC treated dH2O    10µl 
(10x) HY Reaction Buffer    4µl 
Biotin-labelled ribonucleotide    4µl 
DTT        4µl 
RNase Inhibitor Mix     4µl 
T7 RNA Polymerase     2µl 
Final volume     40µl 
 
 
The above reagents were mixed by pipetting and spun as briefly as 
necessary. These were incubated at 370C for 5 hours. The reaction was 
gently mixed every half hour by tapping the tube and spun as briefly as 
necessary, before proceeding to the “Clean-up of cRNA” step. 
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4.9.5 Clean-up of cRNA and quantification 
 
This required the Qiagen Rneasy Mini Kit. The following was added to 
the in vitro transcription tubes (40µl final volume): 
 
DEPC treated H2O    60µl 
 RLT buffer      350µl 
 
The solutions were mixed thoroughly by pipetting. 250µl (100%) ethanol 
was added. The solution was mixed by pipetting but not spun. The sample 
(700µl) was applied to an RNeasy spin column sitting in a 2ml collection 
tube. It was then spun at 8000 xg for 15 seconds.  
The RNeasy spin column was transferred into a new 2ml collection tube. 
500µl RPE buffer was added and spun at 8000 xg for 15 seconds. The 
RNeasy spin column was transferred into a new 2 ml collection tube. 
500µl RPE buffer was added, and spun at maximum speed for 2 minutes. 
The spin column was transferred to a fresh 2ml tube to prevent any carry-
over of the RPE buffer. It was then spun at maximum speed for 1 minute 
to dry the RNeasy membrane from ethanol. The spin column was 
transfered into a new 1.5ml collection tube. The cRNA was eluted by 
placing 50µl DEPC dH2O on the middle of the membrane of the column. 
It was left at room temperature for a couple of minutes, then spun at 8000 
xg for 1 minute to elute. 
 
The Ribogreen RNA Quantification Kit (see previously in Methods) was 
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used to discover the concentration of cRNA. The minimum required 
cRNA concentration for the Affymetrix chip is 0.6µg/ul. 
A sample of the cRNA (500ng-1µg)(denature cRNA at 65-700C for 10 
minutes in denaturing loading buffer) was run on a 1% agarose gel along 
with a marker spanning 200bp to 3 kb (a DNA marker gives a rough idea 
of the size). The product should look like smear from about 100 bp to 2 
kb with a brighter region from 500bp to 1 kb. Denaturing loading buffer 
contained: 
(10x) MOPS       0.5µl 
Deionized Formamide      5µl 
Formaldehyde 37%      1.75µl 
(10x) loading buffer (50% glycerol, 0.1 mg/ml BB) 1µl 
DEPC treated dH2O      1.7µl 
EtBr (10mg/ml)       0.05µl 
 
Final volume       10µl 
 
10µl was added to 1-1.5µg of cRNA 
It was then frozen by placing tube on dry ice and storing at –800C. 
 
The following was added to the eluate: 
  0.5 x volume NH40Ac (7.5M)  
  2.5 x volumes Ethanol (100%) ice cold 
 
It was precipitated at –200C for 1 hour to overnight. It was then spun at 
maximum for 30 minutes at 4 0C. The pellet was washed twice with 
500µl (80%) cold ethanol, and spun at maximum for 5 minutes. All the 
ethanol was removed with a pipette (spun again to collect any residual 
ethanol on the sides of the tube and ethanol was removed a second time 
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using a pipette). The pellet was allowed to air dry for 5-10 minutes. It was 
then resuspended to a final concentration of 1 or 2 µg/µl. The tube was 
placed on dry ice to freeze and then stored at –800C or proceed directly to 
cRNA fragmentation. 
 
4.9.6 cRNA Fragmentation 
 
Example for 0.75µg/µl final concentration: 
 
30µg cRNA          1 to 32µl 
5x Fragmentation Buffer    8µl 
DEPC treated dH2O    to 40µl 
 
5x Fragmentation Buffer (200mM Tris-acetate, pH 8.1, 500mM 
KOAc,150mM MgOAc) 
The fragmentation buffer is made with Rnase free reagents. Tris-
containing solutions should not be treated with DEPC; however once H2O 
has been DEPC-treated it can be used for making the Tris solution. 
The following components were combined to a total volume of 20mL. 
 
4.0mL 1M Tris acetate pH8.1 (Triza base adjusted with glacial acid) 
0.64g MgOAc 
0.98g KOAc 
DEPC-treated H2O to 20 mL 
 
They should be mixed thoroughly and filtered through a 0.2um vacuum 
filter unit. They were then aliqoted and stored at room temperature. 
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They were then incubated at 940C for 35 minutes in a PCR block, and 
then placed on ice after incubation. A sample of the fragmented cRNA 
(~1µg) was run on a 1% agarose gel along with a marker spanning 200bp 
to 3 kb (a DNA marker gives a rough idea of the size). The fragmentation 
should produce a distribution of RNA fragment sizes from approximately 
35 to 200 bases. The fragmented cRNA was stored undiluted at –800C 
until ready to perform the hybridisation. 
 
 
 
4.9.7 Hybridisation Cocktail for human HGU133A arrays 
 
Before adding to the cocktail, one vial of the 20x Eukaryotic 
Hybridisation Controls and one vial of the Oligo B2 were heated at 650C 
for 5 minutes. The two vials were completely thawed before heating. 
They were vortexed for complete mixing then spun briefly. The following  
were mixed for each target: 
  
 
Fragment cRNA     15µg 
Control Oligonucleotide B2   5µl 
20x Eukaroyatic Hybridisation Controls 15µl 
Herring sperm DNA (10mg/ml)   3µl 
Acetylated BSA (50mg/ml)   3µl 
2x Hybridisation buffer    150µl 
 
DEPC dH2O to final volume   300µl 
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2x Hybridisation buffer (Final 1X concentration is 100mM MES, 1M 
[NaCl], 20mM EDTA, 0.01% Tween 20) 
For 50 mL: 
8.3 mL of 12X MES Stock 
17.7mL of 5M NaCl 
4.0mL of 0.5 M EDTA 
0.1mL of 10% Tween 20 
19.9mL of water 
store at 2_80C,  and shield from light 
 
 
The tissue samples were sent to the Affymetrix operator for washing, 
staining and scanning of U133A chips. U133A chips were equilibrated to 
room temperature for use. The probe cocktail was heated to 95oC for 5 
minutes, cooled to 48oC then centrifuged at top speed for 5 minutes. The 
probe cocktail was hybridised to the chip overnight at 45oC in a rotating 
hybridization oven set at 60rpm. Next day the cocktail was removed and 
replaced with low stringency wash buffer. The chips were washed and 
stained with Streptavidin Phycoeurythrin (SAPE) in a GeneChip 400 
Fluidics wash station using protocol EukGE_WS2v4. Chips were scanned 
using an Agilent GeneArray 2500 Scanner. Data supplied was an average 
of 2 scans. 
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 5. Statistical Evaluations 
 
All statistical calculations were carried out using Stats Direct (Ashwell, 
Herts, UK). P values<0.05 were considered significant. 
 
5.1. RT-PCR data 
 
All RT-PCR data was expressed as a copy number per µg total RNA. The 
median value was calculated for normal and malignant tissue for each 
marker.  The differences in median copy number between tissue types for 
each marker were then calculated using non-parametric tests (Mann 
Whitney U). 
 
In order to determine any correlation between markers, Spearman Rank 
correlation was used. In order to assess any correlation between IGF-1 
mRNA expression and clinico-pathological variables, samples were 
divided according to each variable i.e. ER positive, ER negative, lymph 
node positive and lymph node negative. The difference in median copy 
numbers for each variable was then calculated using a non-parametric 
test, Mann Whitney U. 
 
5.2 IGF-1 protein expression 
 
The differences in staining between the normal breast tissue versus 
tumour and stromal versus epithelial staining were evaluated using a two 
sided Fisher exact test or a chi-square test as appropriate. Correlation with 
clinicopathological parameters used Spearmen rank correlation. 
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 5.3 Serum IGF-1 and IGFBP-3 levels 
 
In order to calculate differences in serum IGF-1 and IGFBP-3 levels in 
pre and post-operative breast cancer patients, Mann Whitney U non-
parametric tests were used. For determining the IGF-1 ratio for each 
patient, each value was first corrected for age and then ratios were 
obtained and compared again using the Mann Whitney U test. 
 
 
5.4 Tissue explant culture  
 
For MTS and LDH assays absorbance readings were recorded and mean 
values and standard errors of the mean were calculated. The differences 
were then compared using the Mann Whitney U test. 
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6.0 Results 
 
 
6.1 Results of the RNA quantification 
 
 
 
6.1.1 Ribogreen standard curve results 
 
 
 
Table 2 demonstrates the RNA concentration of normal and malignant 
breast samples using the Ribogreen Method. Each value is a mean of 3 
values of fluorescence. The Ribogreen method is particularly useful for 
detecting smaller concentrations of RNA. For example, it can be seen that 
normal breast tissue produces approximately 3-4 fold less RNA than 
breast tumours. This technique was therefore used to detect the smaller 
quantities of RNA extracted from normal breast tissue. Unfortunately, 
unlike the Agilent Bioanalyzer, this technique only provides information 
on quantity and not quality of RNA. 
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Table 2 RNA concentration (ng/ul) quantified using Ribogreen 
Normal RNA conc ng/ul Tumour RNA conc ng/ul 
100N 62.31 101T 32.3 
106N 150.66 104T 14.27 
108N 125.83 107T 31.26 
109N 3.48 108T 325.8 
110N 29.91 109T 158.36 
111N 68.83 110T 394.26 
112N 15.23 111T 28.59 
113N 34.94 116T 273.51 
114N 10.1 118T 60.22 
116N 6.14 119T 128.99 
117N 8.55 120T 142.64 
118N 22.26 121T 99.36 
121N 7.02 122T 184.65 
122N 13.11 123T 146.39 
123N 23.75 124T 143.45 
124N 103.93 126T 126.99 
125N 26.29 127T 240.68 
126N 76.83 128T 521.35 
127N 20.36 129T 150.08 
129N 28.35 130T 3.04 
130N 6.91 131T 15.82 
131N 6.08 132T 67.15 
132N 3.14 133T 11.89 
133N 18.59 134T 71.35 
134N 5.44 136T 97.5 
135N 4.58 135T 99.81 
137N 5.47 137T 28.52 
139N 6.17 140T 595.3 
140N 55.49 141T 127.75 
147N 12.96 147T 201.9 
150N 35.32 150T 197.84 
153N 14.26 153T 28.25 
155N 5.31 155T 61.17 
156N 42.83 156T 331.07 
157N 44.31 157T 353.93 
160N 17.35 160T 95.69 
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6.1.2 Results of Agilent Bioanalyzer 
 
For each lab chip analysed, the well marker ladder should produce 7 clear 
peaks in order to confirm that the gel has worked (Fig 9). Figure 10 
shows a typical electropherogram and an autoradiograph of extracted 
RNA from a breast sample using the Agilent Bioanalyzer. The graph 
shows three peaks, the first is a marker and indicates if the gel is working 
well. The next two peaks represent the two ribosomal peaks, with a ratio 
that should be 2:1 (28S:18S). This ratio in conjunction with a smooth 
baseline indicates good quality RNA. RNA degradation is seen with a 
decreasing ratio of ribosomal bands, additional peaks and a decrease in 
the RNA signal or shorter fragments. The height of the peaks should also 
compare well with the marker peak thereby indicating a good 
concentration of RNA. The Agilent software is then able to calculate the 
ratio of the sample peaks to the marker peak thereby providing the RNA 
concentration for each sample. 
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Figure 9 Representative electropherogram (A) and 
autoradiograph (B) of a single RNA sample. The ladder 
demonstrates 6 RNA peaks and 1 marker peak. The marker 
allows comparison with other chips. 
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Figure 10. Electropherogram of extracted RNA from a 
breast sample demonstrating high quality and quantity of 
total RNA. Two ribosomal peaks are seen with a ration of 
2:1. 
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6.2 Results from RT-PCR 
 
6.2.1 Results from generation of standard curve 
from amplicons 
 
A linear graph was constructed for each amplicon, the high and low Ct 
values were discarded to correct for pipetting errors and the average of 
the remaining values was calculated. The Ct value is inversely 
proportional to the log of the initial copy number122. Standard curves were 
constructed by plotting the Ct values with 95% confidence intervals 
against the logarithm of the initial copy numbers. The copy numbers for 
each of the experimental samples were than calculated after real-time 
amplification from the linear regression of that standard curve. 
 
Figure 11 demonstrates the amplification plot of IGF-1 amplicon. Serial 
dilutions of the IGF-1 amplicon were diluted as previously described. The 
run was repeated if successful amplification did not occur. 
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Figure 11. Amplification plot of IGF-1 amplicons. Serial 
dilutions result in different fluorescence values. The smaller 
the Ct value, the higher the concentration of DNA. 
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 Table 3. IGF-1 expression in normal and malignant breast tissue 
 
      
      
Normal IGF-1  Tumours        IGF-1   
108N 4.82E+06  108T 1.35E+06  
109N 3.06E+06  109T 9.83E+05  
111N 7.64E+06  111T 6.45E+06  
116N 4.87E+06  116T 4.02E+07  
118N 3.24E+07  118T 1.17E+07  
121N 2.48E+07  121T 4.80E+06  
122N 2.74E+07  122T 2.22E+07  
123N 2.04E+07  123T 1.16E+07  
124N 7.80E+07  124T 6.80E+06  
126N 2.98E+07  126T 4.53E+07  
127N 8.68E+06  127T 1.24E+06  
129N 1.21E+07  129T 1.34E+07  
130N 4.28E+07  130T 0.00E+00  
131N 3.93E+06  131T 5.07E+05  
132N 1.43E+07  132T 2.95E+06  
133N 1.03E+07  133T 3.61E+07  
134N 2.45E+07  134T 0.00E+00  
135N 0.00E+00  135T 3.36E+06  
136N 7.83E+07  136T 5.29E+06  
137N 4.91E+07  137T 1.50E+07  
140N 7.88E+06  140T 1.61E+06  
147N 3.65E+07  147T 1.62E+07  
150N 1.18E+07  150T 2.65E+06  
153N 2.40E+07  153T 1.48E+07  
155N 1.03E+06  155T 1.67E+05  
156N 3.39E+06  156T 1.49E+05  
157N 4.54E+06  157T 1.10E+07  
160N 3.24E+06  160T 1.15E+07  
162N 2.74E+04  162T 2.74E+04  
164N 3.19E+07  164T 9.18E+06  
166N 1.67E+07  166T 2.36E+07  
167N 5.48E+06  167T 0.00E+00  
172N 7.96E+06  172T 0.00E+00  
173N 2.54E+06  173T 4.57E+05  
174N 2.14E+06  174T 2.23E+06  
175N 3.60E+07  175T 4.08E+06  
176N 8.54E+06  176T 1.24E+07  
178N 3.36E+07  178T 7.16E+06  
181N 9.30E+06  181T 6.33E+06  
183N 1.23E+07  183T 5.18E+06  
184N 4.11E+07  184T 2.63E+07  
185N 3.65E+07  185T 2.51E+06  
186N 2.80E+07  186T 2.78E+06  
187N 0.00E+00  187T 0.00E+00  
101 
 
194N 0.00E+00  194T 2.15E+06  
196N 1.26E+07  196T 1.04E+07  
200N 4.65E+06  200L 6.81E+06  
202N 1.43E+07  202T 0.00E+00  
203N 1.76E+07  203T 1.02E+07  
204N 1.48E+07  204T 0.00E+00  
205N 1.17E+07  205T 9.55E+06  
206N 5.52E+06  206T 2.19E+06  
209N 2.59E+06  209T 2.07E+07  
210N 4.21E+06  210T 3.63E+05  
212N 6.60E+06  212T 7.52E+05  
215N 3.08E+05  215L 3.30E+06  
216N 1.04E+06  216L 2.60E+06  
217N 9.22E+06  217T 0.00E+00  
218N 2.60E+06  218T 1.41E+06  
220N 4.98E+06  220T 4.72E+05  
225N 8.53E+05  225T 2.29E+06  
227L 1.37E+05  227T 2.23E+05  
232N 5.39E+06  232T 1.97E+06  
234N 2.68E+06  234T 9.45E+06  
241N1 1.01E+06  241T 4.22E+04  
242N2 3.66E+06  242T 6.05E+05  
243N2 3.15E+05  243T 0.00E+00  
245N2 2.24E+05  245T 1.23E+05  
248N2 3.98E+05  248T 2.25E+06  
249N2 8.21E+05  249T 3.29E+04  
258N 1.37E+06  258T 3.74E+06  
259N 7.24E+04  259T 0.00E+00  
269N 1.87E+06  269T 2.38E+06  
273N 1.12E+06  273T 3.97E+05  
278N 7.01E+06  278T  8.12E+05  
 
Normal IGF-1  Tumours IGF-1 
100NB 3.45E+06  101T 6.69E+06
106N 2.45E+06  104T 2.67E+06
110N 1.82E+07  107T 1.24E+06
112N1 4.44E+06  115T 3.03E+06
113N 1.44E+07  119T 5.97E+06
117N 2.27E+06  128T 1.39E+05
139N 2.42E+06  141T 1.10E+05
149N 7.84E+05  157T1 1.80E+03
154N 1.25E+06  161T 1.52E+06
159N1 3.37E+06  189T 6.14E+06
165N 5.79E+07  192T 2.87E+06
168N 8.37E+05  193T 1.48E+07
169N 7.20E+06  195T 5.70E+05
170N 1.93E+06  197T 2.93E+05
171N 1.03E+07  199L 1.33E+06
177N2 1.71E+06  214L 4.14E+05
182N 9.37E+05  222T 1.78E+05
102 
 
191N 1.12E+07  223T 1.85E+05
198N 4.84E+06  224L 1.43E+08
199N 5.32E+03  233L 1.12E+07
201N 8.04E+06  266T 1.85E+06
207N 0.00E+00  267T 9.49E+05
208N 4.91E+07  279T 5.57E+05
221N 9.92E+05    
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6.2.2 Results from individual markers 
 
6.2.2.1 IGF-1 mRNA 
 
IGF-1 mRNA was significantly down regulated in breast tumours 
compared to normal breast tissue, 2.3x106 copy no/g total RNA in 
tumours vs 6.6x106 in normal breast tissue, p<0.0001. The range for IGF-
1 mRNA expression in breast tumours is 1.80x103 – 1.43x108. The range 
within normal breast tissue expression is 5.32x103- 7.83x107. In addition 
10 tumours (4%) and 4 normal tissues (2%) did not express IGF-1 at all 
indicating an IGF-1 negative sub-group of breast tumours. 
Looking at IGF-1 expression and correlating with clinical characteristics 
there was a significant increase in IGF-1 expression in lymph node 
positive tumours compared to lymph node negative tumours, 6.9x106 
copy number/g total RNA in lymph node positive  vs 1.5x106 in lymph 
node negative tumours (p=0.03). 
There was also an increase in IGF-1 expression in grade 2 and 3 tumours 
compared to grade 1 tumours, 7.9x106 copy number/g total RNA in 
grade 2 and 3 tumours vs 2.6x106 in grade 1 tumours (p=0.05). 
There was no significant difference in IGF-1 expression in presence of 
DCIS, vascular invasion, ER and PR status. 
  
 
6.2.2.2 IGF-1 Receptor 
 
This was expressed in all normal and malignant samples, with significant 
increase in expression in malignant tissue compared to normal tissue, 
2.25x107 copy number/g total RNA in malignant tissue vs 1.17x107 in 
normal tissue, p=0.003.  
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6.2.2.3 IGFBP-3 
 
All the breast samples expressed IGFBP-3. There was a high level of 
expression of IGFBP-3 in all samples but no difference between the 
expression in normal and tumour tissue, 1.86x108 copy no/g total RNA 
in normal tissue vs 1.71x108 in malignant tissue, non significant, p=not 
significant. 
 
6.2.2.4 Growth hormone 
 
In all the samples both normal and malignant expressed low levels of 
growth hormone with no significant difference between the two groups. 
Normal tissue vs malignant tissue was 8.4x104 copy no/g total RNA vs 
3.18x105, p=0.08. 
 
6.2.2.5 Growth Hormone Receptor 
 
Growth Hormone Receptor (GHR) was expressed in both normal and 
malignant tissue, but was significantly over expressed in normal tissue. 
4.78x108 copy number/µg total RNA in normal tissue vs 1.66x107 in the 
malignant samples, p=0.0001. 
 
6.2.2.6 Ghrelin 
 
Ghrelin was found to be expressed in normal and malignant tissue with 
no statistical significant difference between the two. 3.2x105 copy 
number/µg total RNA in normal tissue vs 5.24x105 in the malignant 
tissue, p=not significant 
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6.2.2.7 Ghrelin 1B Receptor 
 
Ghrelin 1B receptor (Ghr-1B-Rec) was expressed in normal and 
malignant tissue with no significant difference between the two groups. 
5.5x105 copy number/µg total RNA in normal tissue vs 2.8x105 in 
malignant tissue, p=not significant. 
 
 
 
6.2.2.8 Somatostatin 
 
This was expressed in normal and malignant tissue with no significant 
difference in the expression, 3.46x105 copy number/µg total RNA in 
normal tissue vs 2.07x105 in malignant tissue, p=not significant. However 
when IGF-1 positive and IGF-1 negative samples were compared there 
was significantly increased expression of somatostatin in the IGF-1 
negative samples, 9.8x108 copy number/µg total RNA in the IGF-1 
negative samples vs 1.07x105 in the IGF-1 positive samples, p=0.002. 
 
 
6.2.2.9 Somatostatin Receptor 5 
 
This was expressed in normal and malignant tissue with no significant 
difference between the two tissues, 9.8x105 copy number/µg total RNA in 
normal tissue vs 5.2x105 in malignant tissue, p=not significant. In 
addition there was no difference between the IGF-1 positive and negative 
samples, 7.35x105 vs 2.5x105, p=not significant. 
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6.2.2.10 C-myc 
 
C-myc was found to be expressed in both normal and malignant tissue at 
similar levels. 8.06x107 copy number/µg total RNA in normal tissue vs 
9.09x107 in malignant tissue, p=not significant. 
 
6.2.2.11 COX-2 
All samples expressed Cox-2 mRNA. There was no significant difference 
between normal or malignant tissues, 2.55x107 copy number/µg total 
RNA in normal tissue vs 1.5x107 in malignant tissue, p=not significant. 
 
6.2.2.12 PCNA 
 
PCNA was expressed in normal and malignant tissue, and significantly 
was over expressed in tumours compared to normal tissue. 5.4x106 copy 
number/µg total RNA in malignant tissue vs 2.8x106 in normal tissue, 
p=0.014. 
 
6.2.2.13 VEGF-165 
Normal and malignant samples expressed VEGF with significant 
overexpression in malignant tissue compared to normal tissue. 5.88x108 
copy number/µg total RNA in malignant tissue vs 1.13x108 in normal 
tissue, p=0.01. 
 
6.2.2.14 VEGF-189 
VEGF was expressed in both normal and malignant tissue with no 
significant difference in the amount of expression between the two 
groups. 6.79x106 copy number/µg total RNA in normal tissue vs 1.41x107 
in malignant tissue, p=not significant. 
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6.2.2.15 1 alpha hydroxylase 
The normal and tumour breast sample tissue expressed similar levels of 1 
alpha hydroxylase, with no significant difference between the groups, 
normal vs tumour was 2.12x107 copy number/µg total RNA vs 3.19x107, 
p=not significant. 
 
6.2.2.16 Vitamin D Receptor 
Median VDR mRNA levels were significantly higher in tumours than 
normal tissue, 3.06x106 copy number/µg total RNA in malignant tissue vs 
1.7x106 in normal tissue, p=0.002. 
 
6.2.2.17 HTERT 
HTERT was expressed in both normal and malignant tissue, but 
statistically was over expressed in malignant tissue. 1.3x105 copy 
number/µg total RNA in malignant tissue vs 1.45x102 in normal tissue, 
p=0.0000007. 
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Table 4. RT-PCR expression of markers in malignant 
and normal breast tissue. A positive correlation is 
seen with IGF-1, IGFR, GHR, PCNA, VEGF 165, 
Vitamin D receptor and HTERT. 
 
Marker Tumour Normal P value 
IGF-1 2.3x106 6.6x106 P<0.0001 
IGFR 2.25x107 1.17x107 P=0.003 
IGFBP-3 1.71x108 1.86x108 P=n.s. 
GH 3.18x105 8.4x104 P=n.s. 
GHR 1.66x107 4.78x108 P=0.0001 
Ghrelin 5.24x105 3.2x105 P=n.s. 
Ghrelin 1B 
receptor 
2.8x105 5.5x105 P=n.s. 
Somatostatin 2.07x105 3.46x105 P=n.s. 
Somatostatin 
receptor 5 
5.2x105 9.8x105 P=n.s. 
cmyc 9.09x107 8.06x107 P=n.s. 
Cox-2 1.5x107 2.55x107 P=n.s. 
PCNA 5.4x106 2.8x106 P=0.014 
VEGF 165 5.88x108 1.13x108 P=0.01 
VEGF 189 1.41x107 6.79x106 P=n.s. 
1 alpha 
hydroxylase 
3.19x107 2.12x107 P=n.s. 
Vitamin D 
receptor 
3.06x106 1.7x106 P=0.0017 
HTERT 1.3x105 1.45x102 P=0.0000007
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Table 4  Statistics: RT-PCR expression of markers in 
malignant and normal breast tissue 
 
 
 
 
 
 
 
 
    
1.  IGF-1 Mann-Whitney U test 
Observations (x) in N-IGF-1 =75 median=6641960.35879 Normal 
Observations (y) in T-IGF-1 =75 median=2332396.79075 Tumour 
Normalised statistic=4.045925 (adjusted for ties) 
Lower side p>0.9999 (H1: x tends to be less than y) 
Upper side p<0.0001 (H1: x tends to be greater than y) 
Two sided p<0.0001(H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=3430 median difference =3819731.4 
CI=1800401.3 to 7007661.3 
 
 
 
 
 
 
 
2. IGFR Mann-Whitney U test 
Observations (x) in N-IGFR=75 median=11734367.45493 Normal 
Observations (y) in T-IGFR=75 median=22521443.790011 Tumour 
Normalised statistic=0.508682 
Lower side p=0.9981 (H1: x tends to be less than y) 
Upper side p=0.0019 (H1: x tends to be greater than y) 
Two sided p=0.0038 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=1163 median difference=4652398.6 
CI=1377619.7 to 9169386.1 
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3. IGFBP-3 Mann-Whitney U test 
Observations (x) in N-IGFBP3=32 median=186400000 Normal 
Observations (y) in T-IGFBP3=32 median=171256350 Tumour 
Normalised statistic=0.993621 (adjusted for ties) 
Lower side p=0.8397962 (H1: x tends to be less than y) 
Upper side p=0.1602038 (H1: x tends to be greater than y) 
Two sided p=0.3204075 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=367  median difference=2795000 
CI=-2500000 to 9850000 
 
 
 
 
 
4. GH  Mann-Whitney U test 
Observations (x) in N-GH=32 median=84046.993943 
Observations (y) in T-GH=32 median=318296.59651 
Normalised statistic=-1.718676 
Lower side p=0.0428367 (H1: x tends to be less than y) 
Upper side p=0.9571633 (H1: x tends to be greater than y) 
Two sided p=0.0856734 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=367  median difference=-100649.45 
CI=-764170.2 to 6086.8 
 
 
 
 
 
5. GHR Mann-Whitney U test 
Observations (x) in N-GH-R=32 median=478500000 
Observations (y) in T-GH-R=32 median=16650000 
Normalised statistic=4.994958 (adjusted for ties) 
Lower side p=0.9999997 (H1: x tends to be less than y) 
Upper side p=0.0003 (H1: x tends to be greater than y) 
Two sided p=0.0001 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=428  median difference=-88348.249 
CI=-196236.464 to -21046.492 
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6.Ghrelin Mann-Whitney U test 
Observations (x) in N-Ghrelin=32 median=323500 
Observations (y) in T-Ghrelin=32 median=524000 
Normalised statistic=-1.45688 (adjusted for ties) 
Lower side p=0.0725748 (H1: x tends to be less than y) 
Upper side p=0.9274252 (H1: x tends to be greater than y) 
Two sided p=0.1451496 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=367  median difference=-198800 
CI=-2031000 to 43100 
 
 
 
 
 
 
7. Ghrelin 1B receptor Mann-Whitney U test 
Observations (x) in N-Ghr-1B-Rec=32 median=551345 
Observations (y) in T-Ghr-1B-Res=32 median=283255 
Normalised statistic=-1.000518 (adjusted for ties) 
Lower side p=0.84147 (H1: x tends to be less than y) 
Upper side p=0.15853 (H1: x tends to be greater than y) 
Two sided p=0.31706 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=367  median difference=-1470.5 
CI=-858000 to 10 
 
 
 
 
 
 
 
8. c-Myc Mann-Whitney U test 
Observations (x) in N-c-Myc=32 median=80600000 
Observations (y) in T-c-Myc=32 median=90950000 
Normalised statistic=-0.657938 (adjusted for ties) 
Lower side p=0.255289 (H1: x tends to be less than y) 
Upper side p=0.744711 (H1: x tends to be greater than y) 
Two sided p=0.5105779 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=367  median difference=-14150000 
CI=-51200000 to 27410000 
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9. PCNA Mann-Whitney U test 
Observations (x) in N-PCNA =31 median=2870721.219345 
Observations (y) in T-PCNA=31 median=5400355.815812 
Normalised statistic=-2.447174 
Lower side p=0.0071991 (H1: x tends to be less than y) 
Upper side p=0.9928009 (H1: x tends to be greater than y) 
Two sided p=0.0143981 (H1: x tends to be distributed differently to y) 
 
95% confidence interval for difference between medians or means: 
K=355  median difference=-2277556.7 
CI=-5153821.9 to -442362.6 
 
 
 
 
 
 
 
 
10. VEGF-165 Mann-Whitney U test 
Observations (x) in N-VEGF-165=35 median=113000000 
Observations (y) in T-VEGF-165=35 median=588000000 
Exact probability: 
Lower side p=0.005628 (H1: x tends to be less than y) 
Upper side p=0.994372 (H1: x tends to be greater than y) 
Two sided p=0.011256 (H1: x tends to be distributed differently to y) 
 
95.5% confidence interval for difference between medians or means: 
K=65  median difference=-452333 
CI=-234553  to 4352227 
 
 
 
 
 
 
11. VEGF-189 Mann-Whitney U test 
Observations (x) in N-VEGF-189=35 median=6790000 
Observations (y) in T-VEGF-189=35 median=14100000 
Exact probability: 
Lower side p=0.1834376 (H1: x tends to be less than y) 
Upper side p=0.8165624 (H1: x tends to be greater than y) 
Two sided p= 0.3668752 (H1: x tends to be distributed differently to y) 
 
95.5% confidence interval for difference between medians or means: 
K=65  median difference=-4710000 
CI=-26800000 to 5380000 
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12. HTERT  Mann-Whitney U test 
Observations (x) in N-HTERT=35  median=145 
Observations (Y) in T-HTERT=35  median=130000 
Exact probability (adjusted for ties) 
Lower side p=0.0000003 (H: x tends to be less than y) 
Upper side p=0.9999997 (H: x tends to be greater than y) 
Two sided p=0.0000007 (H: x tends to be distributed differently to y) 
 
95.1% confidence interval for differences between medians or means: 
K=341  median difference=-117872.5 
CI=-176831 to -20560 
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6.3 Results from Immunohistochemistry 
 
 
 
 
6.3.1 Results of IGF-1 staining 
 
6.3.1.1 DAB staining 
 
Immunohistochemical DAB staining of the liver showed staining of IGF-
1, with the negative samples not staining up, unlike the positive samples 
(Figure 12). In addition staining of IGF-1 in normal and malignant breast 
samples showed that all tissue samples expressed IGF-1 apart from the 
IGF-1 negative samples which showed no DAB staining (Figure 13). 
 
6.3.1.2 Fluorescent staining 
 
When the breast tumours were then stained with fluoresceine dye, 
positive staining was noted in the stroma of the tissue (Figure 14). In 
accordance with the DAB immunohistochemistry there was absence of 
staining in the IGF-1 negative samples. 
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Figure 12- IGF-1 staining of liver 
 
 
 
 
A – Liver negative control           B-Liver staining positive for IGF-1 
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Figure 13- IGF-1 staining of malignant breast 
tissue 
 
 
    
 
A   Negative control breast tumour staining    B Breast tumour staining positive for IGF-1                        
C No staining in IGF-1 negative tumour  D Staining in IGF-1 positive tumour 
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Figure 14 – Fluorescent IGF-1 staining of 
malignant breast tissue 
 
 
 
 
A – Negative control                          B – IGF-1staining breast tissue            
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6.3.2 Results of GH staining 
 
The normal and malignant breast tissue samples were then fluorescently  
stained for Growth Hormone (GH). All 10 samples were positive for 
staining with Growth hormone with a wide area of staining visible, in 
both the stroma and epithelial cells of the tissue. 13 negative samples 
were produced without the stain and these were totally negative results 
with little staining visible, therefore they were dark in nature. 
 
 
 
6.3.3 Results of Ghrelin staining 
 
Immunohistochemical staining of ghrelin in normal and malignant breast 
tissue was done using fluorescent staining. The samples showed extent 
widespread staining of fluorescence throughout the tissue (see figure 15). 
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Figure 15- Ghrelin staining of 
breast 
 
 
 
B –ve x20  10347-E3-01 (Ghrelin) B +ve x20  10347-E3-01 (Ghrelin)
 
Negative control                     Normal breast tissue 
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6.4 Results of serum IGF-1 and IGFBP-3 
 
6.4.1 Serum IGF-1 
 
There were two groups of women, those who had IGF-1 and IGFBP-3 
blood tests prior to surgery, pre-operative group involving 36 women, and 
those who had blood tests some time after their breast surgery, post-
operative group involving 35 women. These women were not paired.  In 
the pre-operative women, the mean age was 61 years and the mean IGF-1 
was 162ng/ml (range 100-425ng/ml). In one woman her IGF-1 level was 
actually elevated above the normal range (a 36 year old lady with IGF-1 
of 425). In the post-operative women the mean age was 58 years and the 
average IGF-1 was 145ng/ml (range 56-257ng/ml). No women had IGF-1 
levels elevated above the normal range. Within the post-operative group 
32 (82%) women were taking Tamoxifen (T) and 7 (18%) women were 
not (NT). The mean age of patients in NT was 55 years and the average 
IGF-1 was 155ng/ml (range 130-197ng/ml). In the T group the mean age 
was 57 years, the average IGF-1 was 145mg/ml (range 62-257ng/ml). 
 
As IGF-1 levels are age-dependant, the IGF-1 levels of all of the subjects 
were corrected for age, according to the normal ranges for each age range 
(table 3) and expressed as a ratio of upper limit of age related normal 
range (table 4). Using this correction, serum IGF-1 levels were 
significantly decreased in the post-operative patients taking tamoxifen 
when compared to pre-operative patients and post-operative patients not 
taking tamoxifen (Mann Whitney, p<0.05) 
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 Table 5. Normal serum values of IGF-1 
 
Age (years) Normal (min-max) serum IGF-1 
concentration (ng/ml) 
19-29 125-329 
30-39 120-330 
40-49 126-369 
50-59 108-263 
60-83 108-229 
 
 
 
 
 
 
 
 
 
 
Table 6. Serum IGF-1 levels expressed as a ratio of the 
upper limit of the age related normal range. 
 Median ratio +/- standard deviation 
Pre-operative 0.6 +/- 0.18* 
Post-operative NT 0.62+/- 0.14* 
Post-operative T 0.52+- 0.14 
 
*= p<0.05 (Mann Whitney U), when compared to post-operative T. 
 
 
6.4.2 IGFBP-3 
 
Serum IGFBP-3 levels increase from late childhood to puberty and then 
fall gradually during adult life. The levels are also higher in females than 
males (normal range 2.6-5.5mg/l in women versus 1.5-4.6mg/l in men). 
 
In the pre-operative group, the mean patient age was 61 years and the 
mean serum IGFBP-3 level was 3mg/l (range 1.6-5.5mg/l). In the post-
operative group, the mean patient age was 64 years and the average 
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IGFBP-3 was 3.1mg/l (range 1.3-5.3mg/l). Within this post-operative 
group, 28 (80%) patients were taking tamoxifen (T) and 7 (20%) were not 
(NT). The average age of the NT group was 62 years and the average 
IGFBP-3 level was 2.8mg/l (range 1.4-5.2mg/l). The average age of the T 
group was 55 years with a mean IGFBP3 level of 3.0mg/l (range 1.3-
5.3mg/l). Tamoxifen clearly has no effect on serum IGFBP-3 levels. 
 
6.4.3 IGF-1: IGFBP-3 ratio levels 
 
IGFBP3 is the predominant binding protein for IGF-1 and determines its 
activity. The IGF-1:BP-3 ratio was determined for the three groups of 
patients; pre-operative, post-operative NT and post-operative T. To 
account for the age related decline of both peptides, values were 
calculated as a ratio of the upper limit of the age-related normal range 
(Table 5).  
The results show that the IGF-1:BP-3 ratio is significantly higher in the 
pre-operative group than the post-operative T group (Mann Whitney, 
p=0.05). There is no significant difference however between the pre-
operative group and the post-operative group not taking Tamoxifen 
 
 
 
 
 
 Median ratio +/- standard deviation 
Pre-operative 0.051 +/- 0.027* 
Post-operative NT 0.054 +/- 0.03** 
Post-operative T 0.04 +/- 0.013 
Table 7. Serum IGF-1:BP-3 ratio expressed as a ratio of the upper limit of 
the normal range 
 
*p=0.05, when compared to post-operative T 
**p=0.09 when compared to post-operative  
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6.5 Results of viability of cultured breast explants 
 
6.5.1 Primary breast biopsy culture 
 
The breast cancer samples were collected from theatre and taken straight 
to the pathology department. The pathology department gave us normal 
and malignant tissue, which we took back to the lab in a cryogenic tube 
on ice. The samples were then prepared as explained in the methods. 
 
6.5.2 Results of MTS assay 
 
Figure 16 demonstrates the mean absorbance in a representative normal 
and malignant tissue breast tissue explant after 0, 12, 18 and 24 hours 
incubation. The increase in absorbance at 24 hours for both samples 
indicates their viability after 24 hours of culture and a recover of 
metabolic activity after excision. 
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Figure 16:  
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 Figure 17 and 18 indicates MTS results from a normal and malignant 
tissue explant incubated for 96 hours. 
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Figure 17: 
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 Although there is some variation, the absorbance suggests viability at 72 
hours, with a slight decline after 96 hours. It could be seen that normal 
tissue was alive at 96 hours, see figure 18.  
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Figure 18:  
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6.5.3 Results of LDH assay 
 
Figure 19 and 20 demonstrates the absorbance of 2 samples of normal 
and malignant tissue up to 96 hours in the LDH assay. There was a slow 
increase in absorbance over 96 hours. 2% Triton was added to a sample 
of malignant tissue, used as a positive control and shown to have more 
absorbance than the normal and malignant tissue. In figure 19 there is a 
marked increase in LDH release between 24 and 48 hours in the 2% 
Triton sample indicating cell death, which is to be expected. However in 
Figure 20 initially there is a decrease in LDH between 24 and 48 hours in 
the 2% Triton sample which is unexpected. After 48 hours the LDH 
increases, again indicating cell death. 
LDH levels in normal and malignant tissue were steady up to 72 hours, 
but increased at 96 hours in normal sample, again indicating cell death. 
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Figure 19: 
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Figure 20: 
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6.5.4 Effects of ghrelin on the expression of IGF-1 in 
Breast tissue explants 
 
 
Figures 21- 24 shows IGF-1 mRNA levels in normal and malignant 
breast tissue samples that were grown in media only or with ghrelin 
concentration 1ml 10-9M  for up to 48 hours. It can be seen that the 
expression of IGF-1 was significantly reduced in the presence of ghrelin 
when cultured for 24 or 48 hours. 
 
 
Figure 21: 
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Figure 22: 
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Figure 23: 
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Figure 24: 
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 6.6 Microarray analysis of IGF-1mRNA positive and 
negative breast tumours 
 
39 genes were upregulated (>2 fold) in the IGF-1 positive tumours, 
compared to the IGF-1 negative tumours. 27 genes were found to be 
downregulated (<2 fold) in the IGF-1 positive tumours, including 
suppression of tumourigenicity 13. This is an abundant highly conserved 
protein that binds heat shock proteins and has previously been shown to 
be down regulated in breast, colorectal and ovarian carcinoma. 
Expression of local IGF-1 by breast cancers is accompanied by 
differential expression of numerous cancer-associated genes. Clarification 
of these genes will further elucidate the mechanisms by which IGF-1 
influences the pathogenesis of breast cancer.  
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Table 8 – List of genes downregulated in IGF-1 
positive breast cancer 
 
Pos/neg Neg/pos T test Unigene title 
0.26 3.92 0.04 Chromosome 10 open reading frame 2 
0.37 2.69 0.03 Hypothetical protein MGC5306 
0.47 2.14 0.04 Trichorhinophalangeal syndrome 1 
0.48 2.07 0.01 Hypothetical protein /m/gC3731 
0.49 2.06 0.03 Mitochondrial ribosomal protein 63 
0.49 2.03 0.02 HSPC003 protein 
0.50 1.99 0.02 Tumourgenicity 13; ST 13 
0.50 1.99 0.05 Homo sapiens, clone IMAGE:3506202
0.51 1.96 0.01 CGI-115 protein 
0.51 1.94 0.04 Hypothetical protein FLJ10359 
0.52 1.93 0.05 Cysteine and histidine-rich domain 
0.53 1.90 0.04 Endoplasmic reticulum chaperone 
SIL1 
0.54 1.84 0.02 Hypothetical protein FLJ10539 
0.55 1.82 0.05 Hypothetical protein MGC10764 
0.56 1.78 0.05 Hypothetical protein FLJ20257 
0.56 1.78 0.05 Hypothetical ptotein FLJ10514 
0.57 1.76 0.04 Hypothetical protein MGC3262 
0.57 1.74 0.04 Hypothetical protein FLJ10734 
0.58 1.73 0.04 KIAA 1698 protein 
0.59 1,71 0.02 Adenylosuccinate synthase 
0.61 1.63 0.03 Single Ig IL-1-1R-related molecule 
0.63 1.60 0.05 Exosome component Rrp41 
0.63 1.59 0.03 Ring finger protein 7 
0.63 1.59 0.03 Pan-hematopoietic expression 
0.64 1.57 0.01 ATPase inhibitor percursor 
0.64 1.56 0.01 Hypothetical protein FLJ23182 
0.66 1.53 0.04 KIAA0632 protein 
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Talble 9 – List of genes upregulated in IGF-1 
positive breast cancer 
 
Pos/neg    Neg/pos T test Unigene Title 
4.01 0.25 0.02 tubulin, alpha 3 
3.61 0.28 0.02 complement component 1, q subcomponent, alpha polypeptide 
3.61 0.28 0.03 major histocompatibility complex, class II, DR beta 5 
3.52 0.28 0.00 duodenal cytochrome b 
3.35 0.30 0.02 
carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein) 
3.33 0.30 0.01 EphB3 
3.03 0.33 0.05 phosphatidic acid phosphatase type 2A 
3.02 0.33 0.03 ADAM-like, decysin 1 
2.81 0.36 0.04 
myristoylated alanine-rich protein kinase C substrate 
(MARCKS, 80K-L) 
2.81 0.36 0.01 KIAA0603 gene product 
2.78 0.36 0.04 RecQ protein-like (DNA helicase Q1-like) 
2.77 0.36 0.02 SRB7 (suppressor of RNA polymerase B, yeast) homolog 
2.70 0.37 0.02 C-terminal binding protein 1 
2.68 0.37 0.02 myotubularin related protein 1 
2.64 0.38 0.00 stromal cell-derived factor 1 
2.61 0.38 0.03 ephrin-B2 
2.49 0.40 0.02 immunoglobulin heavy constant gamma 3 (G3m marker) 
2.46 0.41 0.03 CGI-26 protein 
2.43 0.41 0.04 cAMP responsive element binding protein-like 2 
2.42 0.41 0.03 translocation protein 1 
2.40 0.42 0.04 Rho GDP dissociation inhibitor (GDI) alpha 
2.37 0.42 0.02 
C-type (calcium dependent, carbohydrate-recognition domain) 
lectin, superfamily member 2 (activation-induced) 
2.34 0.43 0.03 
Homo sapiens cDNA FLJ32313 fis, clone PROST2003232, 
weakly similar to BETA-GLUCURONIDASE PRECURSOR 
(EC 3.2.1.31) 
2.26 0.44 0.03 src family associated phosphoprotein 2 
2.24 0.45 0.04 
S100 calcium-binding protein A4 (calcium protein, calvasculin, 
metastasin, murine placental homolog) 
2.22 0.45 0.01 C-terminal binding protein 1 
2.17 0.46 0.01 KIAA0515 protein 
2.16 0.46 0.03 lysosomal apyrase-like 1 
2.15 0.47 0.04 transforming growth factor, beta 1 
2.11 0.47 0.03 ESTs, Weakly similar to AF208855 1 BM-013 [H.sapiens] 
2.08 0.48 0.01 iduronate 2-sulfatase (Hunter syndrome) 
2.06 0.49 0.02 CD53 antigen 
2.05 0.49 0.02 hypothetical protein FLJ20311 
2.05 0.49 0.03 
SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily a, member 5 
2.04 0.49 0.01 Putative prostate cancer tumor suppressor 
2.03 0.49 0.03 CD58 antigen, (lymphocyte function-associated antigen 3) 
2.02 0.50 0.05 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 
2.01 0.50 0.01 LIV-1 protein, estrogen regulated 
2.01 0.50 0.01 discs, large (Drosophila) homolog 1 
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Figure 25 – Microarray of IGF-1 positive and 
negative breast tumours 
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7. Discussion 
 
 
 
IGF-1 expression in breast tissue 
 
 
This study confirmed the expression of IGF-1 and its receptor in human 
breast tissue. We found using ribogreen that breast tumours produced 3-4 
times more IGF-1 RNA than normal breast tissue. Interestingly using RT-
PCR, IGF-1 appeared to be down regulated in breast tumours compared 
to normal tissue (p<0.0001). In addition we found 10 tumours and 4 
normal samples did not express IGF-1 at all. Previously Peyrat et al did 
not detect IGF-1 mRNA in 4 breast cancers123. This possibly indicates a 
sub group of breast tumours which do not express IGF-1. We found over 
expression of Somatostatin in IGF-1 negative breast tumours compared to 
IGF-1 positive tumours. However no other gene was overexpressed in 
IGF-1 negative tumours. The implication is that IGF-1 negative tumours 
may be more aggressive than IGF-1 positive tumours however more 
research into the clinical details of IGF-1 negative tumours must be 
performed. Another study has similarly shown expression of IGF-1 
mRNA in breast cancer tissue samples, and in situ hybridization studies 
have shown that the message originates from the stromal cells adjacent to 
normal lobules. IGF-1 mRNA however was not found in human breast 
cancer cell lines33.Yee et al also found no IGF-1 mRNA in breast cancer 
cell lines, but RNA extracted from breast tissue had easily detectable 
IGF-1 mRNA. Again in situ hybridization showed the IGF-1 mRNA was 
expressed in the stromal cells, and not by normal or malignant epithelial 
cells32. This could explain how in our study we found IGF-1 to be down 
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regulated in breast tumours compared to normal breast tissue. Similarly 
Chong et al discovered that IGF-1 expression was lower in cancerous 
tissue compared to adjacent non-neoplastic breast tissue, thus supporting 
a paracrine relationship between cancerous tissue and benign breast 
tissue124. A further paper has also shown IGF-1 expression to be lower in 
tumour tissue than normal breast tissue 40. Interestingly they also 
discovered increased IGF-1 mRNA expression in normal breast tissue 
from women with positive family history of breast cancer, indicating that 
IGF-1 may play a role as a breast cancer risk factor.  In conclusion, 
looking at my results, I feel that IGF-1 expression was increased in breast 
tumours compared to normal breast tissue. The RT-PCR results show the 
opposite findings due to IGF-1 mRNA being expressed in stromal cells 
and not by malignant breast cells. 
 
Limitations of RT-PCR 
 
Real-time RT-PCR is now widely used for characterising or confirming 
gene expression patterns and comparing mRNA levels in different sample 
populations. Recent improvements in internal standards, references for 
normalising data and new mathematical models to analyse data have 
improved its use as a possible diagnostic tool. However there remain 
some concerns about how quantitative and informative real-time RT-PCR 
is. A wide variety of protocols exist amongst research laboratories, and 
there is no universally accepted validation of normalising data thereby 
leading to difficulties in reproducing data. Improvements have led to the 
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development of standard templates125 which allows comparison between 
experiments and use of internal standards to reduce variation in template 
starting amounts and operator loading error. 
 
One of the major difficulties with this study was the in vivo RNA 
extraction from whole tissue samples. The heterogeneity of cell types 
within the sample leads to an averaging out of the expression in different 
cell types and perhaps the expression profile of a specific cell type may 
be masked or even lost. Previous studies have shown significant 
differences in gene expressing profiles of microdissected and bulk tissue 
samples. This may be particularly problematic when comparing normal 
and malignant breast tissue. Normal tissue directly adjacent to a tumour 
may be phenotypically normal but it may display an altered gene 
expression due to its proximity to the tumour. In order to overcome this 
problem, we obtained normal breast tissue an average of 10cm away from 
the main tumour site, which was then confirmed as normal tissue by the 
pathology department. 
 
Breast tissue comprises of many different cell types including glandular 
epithelial cells, myoepithelial cells, stromal fibroblasts, adipocytes, 
vascular endothelial cells and others. This will therefore cause a large 
difference in gene expression in normal and malignant breast tissue and 
will confound changes due to malignant tissue only. This issue could be 
addressed by using laser capture microdissection to extract only breast 
tumour cells to look purely at their gene expression only. 
 
Laser capture micodissection is a novel technique that allows the 
extraction of a pure subpopulation of cells from heterogenous in vivo 
tissue samples. A brief laser pulse is directed at cells within a tissue 
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section on a glass slide and individual cells may be selected and gene 
expression then determined at an RNA and protein level. The main 
drawback of this technique is that a very small sample is obtained making 
RNA isolation difficult and good quality RNA is essential for successful 
RT-PCR. This technique is also classically performed using archival 
formalin-fixed paraffin-embedded tissue specimens and the RNA yielded 
from these cells may have undergone extensive degradation and also the 
use of fixatives may well alter the results. New commercial kits have 
been developed in order to overcome these problems and so the future use 
of this technology may improve the validity of our results. 
 
 
 
 
IGF-1R expression and tumour associated genes 
 
We observed that IGF-1R expression was increased in breast tumours and 
previous studies have shown that IGF-1R expressing in primary breast 
tumours is very common24;126;127. Indeed Law et al showed that IGF-1R 
was universally expressed in all breast cancer subtypes (luminal, triple-
negative and HER2+)128. In addition the presence of phosphorylated IGF-
1R could be a predictor for IGF-1 targeted therapy such as monoclonal 
antibodies to IGF-1R129. Currently more than 70 clinical trials involving a 
variety of drugs are underway, with the IGF-1R becoming one of the 
most intensively investigated targets in oncology130. CP-751,871 is a fully 
human IgG2 monoclonal antibody antagonist of IGF-1R which has been 
used in a phase 1 clinical study on patients with refractory solid 
tumours131.  
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PCNA is a proliferation marker and is thought to be closely related to cell 
proliferation. Immunostaining for PCNA is a useful prognostic factor and 
can be used as an indication of the degree of malignancy in breast 
cancer132. It is no surprise that we found PCNA to be increased in 
tumours compared to normal tissue, indicating that more proliferation 
occurs in tumours than normal breast tissue. There was no significant 
difference in PCNA expression in IGF-1 positive or negative tumors.  
  
VEGF is known to be up regulated in several cancers, particularly 
colon133. It plays an important role in tumour angiogenesis134 and in vitro 
studies have shown that IGF-1 regulates VEGF transcription135. We found 
VEGF-165 expression to be significantly upregulated in breast tumours 
compared to normal breast tissue (p=0.01). Interestingly VEGF-189 
expression was not increased. A previous paper has shown that VEGF-
165 but not VEGF-189 stimulates vasculogenesis and bone marrow cell 
migration into Ewing’s sarcoma tumours in vivo136. Kirkpatrick et al 
similarly found VEGF-165 to be significantly over expressed in tumour 
tissue compared to adjacent normal breast tissue{Kirkpatrick, 2004 125 
/id. However VEGF-189 expression in tumour tissue was not 
significantly different to the expression in adjacent non-cancerous tissue. 
This tends to indicate that VEGF-165 is more important in breast 
tumourigenisis than VEGF-189. 
 
Vitamin D is known to inhibit proliferation of breast cancer in vitro and 
in vivo137 and has been shown to block the mitogenic effects of IGF-1138-
140. The mechanism by which this occurs is unclear. It may be due to its 
regulation of IGF-1R139 or upregulation of inhibitory IGFBPs or perhaps 
a modulation of the downstream effects of IGF-1 signalling. We found 
Vitamin D receptor was over expressed in breast tumours related to 
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normal breast tissue. This has previously been reported in other 
studies141;142. No change was seen in 1 alpha hydroxylase expression in 
malignant and normal breast tissue suggesting that paracrine vitamin D is 
not important in breast proliferation. 
 
We observed that hTERT expression was markedly upregulated in breast 
tumours. hTERT has previously been found to be expressed in the 
majority of breast cancers143 with levels being significantly higher in 
breast cancer than in adjacent non-cancerous tissue or fibroadenomas144. 
It has a sensitivity of 50% and a specificity of 90% in the ability to detect 
malignancy in breast tissue. A further study found hTERT mRNA 
expression to be associated with that of the VEGF189 and VEGF 165 
isoforms, suggesting a possible pathway through which high expression 
of hTERT might be linked to worsened disease prognosis145. As VEGF is 
known to increase the likelihood of tumour metastasis it would be 
expected that high levels of hTERT might also be correlated with 
increased lymph node positivity. 
 
GHR was found to be over expressed in normal breast tissue. There is 
expression of GH and GHR in the majority of normal and malignant 
breast cells146. Previous papers have found GHR expression in epithelial 
cells of normal, proliferative and neoplastic lesions of the breast147. There 
has also been demonstrated the stromal expression of GHR genes in 
normal breast tissue. Thus the putative role of Growth hormone in the 
progression of proliferative mammary disorders is not due to grossly 
altered levels of receptor expression147. As GHR has been found in 
malignant and normal cells it is diffcult to explain why GHR was over 
expressed in normal tissue in our study. There was no difference in GHR 
or GH expression in IGF-1 positive or negative breast tumours. 
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 Somatostatin was found to be increased in IGF-1 negative tumours in our 
study. Expression of Somatostatin receptors in human primary breast 
cancer is widespread. Previous papers have shown Somatostatin receptor 
subtype 2 expression being significantly higher in breast cancers than in 
normal breast tissue148. Interestingly we found no significant difference in 
Somatostatin receptor 5 expression levels between tumour and benign 
breast tissue. 
 
Furthermore we found no significant difference in expression of IGFBP-
3, GH, Ghrelin, Ghrelin 1B receptor, cmyc, or Cox-2 in tumour or benign 
breast tissue. There were high levels of IGFBP-3, cmyc and Cox-2 
expressed in both malignant and benign breast tissue. There were medium 
levels of GH, ghrelin and ghrelin 1B receptor expression in malignant and 
benign breast tissue. 
 
Immunohistochemistry 
 
Using immunohistochemical DAB staining we demonstrated IGF-1 
expression in liver and normal and malignant breast samples. We showed 
lots of IGF-1 highlighting when IGF-1 positive samples were stained with 
fluorescence dye, but little staining in IGF-1 negative samples. This 
shows a correlation between the RT-PCR IGF-1 positive or negative 
status of breast tumours and the immunohistochemical staining. 
 
GH staining was seen in all 10 IGF-1 positive samples with a wide area 
of staining visible, and staining was not present in the 13 IGF-1 negative 
samples. 
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Ghrelin immunohistochemical staining was done using fluorescent 
staining and samples showed extent staining throughout the tissue. Again 
this correlates with the RT-PCR expression of ghrelin in all normal and 
malignant breast tissue, showing that ghrein was present in all samples of 
breast tissue. 
 
Serum IGF-1 and IGFBP-3 
 
IGF-1 levels were significantly lower in patients taking Tamoxifen, 
however no effect was seen on serum IGFBP-3 levels. The IGF-1: BP-3 
ratio was also found to be significantly higher in women with breast 
cancer prior to surgery, thereby agreeing with previous epidemiological 
studies. Tamoxifen has been shown to significantly reduce serum levels 
of IGF-131;149-151 but to have no effect on IGFBP-3152. Circulating levels 
of IGF-1 and IGFBP-3 are however strongly affected by nutritional 
status153;154 and catabolic stress that accompanies surgery155;156. This may 
therefore be one of the reasons for a fall in IGF-1 following surgery. 
However in this study no fall in IGF-1 was observed in the group not 
taking Tamoxifen post-operatively. This indicated that the fall in IGF-1 is 
mainly due to Tamoxifen. 
The mechanism by which Tamoxifen alters the IGF-1 axis has not been 
fully elucidated. It is thought that Tamoxifen blocks the oestrogen 
receptor, interfering with the production of growth hormone from the 
pituitary, and so reducing the amount of IGF-1 produced by the liver and 
released into the circulation. One study has also suggested that Tamoxifen 
may work via a pituitary-independent action of reducing IGF-1 in the 
peripheral tissue47. Tamoxifen also has direct anti-oestrogen effects on 
breast cancer cells and may well reduce the amount of IGF-1 and IGFBP-
3 produced by the cells themselves149;157 
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 Primary breast explants culture 
 
We wanted to clarify the expression of IGF-1 in normal and malignant 
breast tissue over 24-48 hours and observe effects that ghrelin would have 
on IGF-1 expression. In order to do this we developed a novel, 
physiologically relevant explant system to provide us with more clinically 
relevant information than cell line work can provide. The main difference 
in methodology involved the use of breast tissue rather than using cancer 
cell lines which have previously undergone many mutations and may not 
be physiologically relevant. There were however a few potential areas for 
error in our experimental technique. One variable factor was the time 
taken to transfer breast tissue from the patient into the experimental 
culture media. In order to standardise this and mimic in vivo conditions, 
all samples were collected immediately after surgical excision and placed 
in media warmed to 37oC. Another variable factor in comparing the 
samples was a difference in weight and composition of breast tissue, 
which may influence supply of oxygen and experimental substance. 
Normal breast tissue in particular consists of a varying amount of fat and 
fibrous tissue which may influence the weight. To minimise this factor, 
all samples were cut into sizes weighing approximately 10-20mg. Every 
effort was made with normal breast tissue to excise all visible fatty tissue 
away so that only glandular tissue was used in experiments.  
The LDH and MTS assays and standardization of absorbance allowed us 
to validate our novel culture technique. The MTS assay is a rapid method 
of assessing cell viability and is used to measure changes in cell viability 
or proliferation. In actively metabolising cells, an increase in MTS 
conversion is spectrophotometrically quantified. Comparison of this value 
to an untreated control provides an increase in cellular metabolic activity. 
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Conversely, in cells that are undergoing apoptosis or necrosis, MTS 
reduction decreases, reflecting the loss of cell viability. 
For the assessment of cell death we used the LDH assay. Cell death or 
cytotoxicity is classically evaluated by the quantification of plasma 
membrane damage. Lactate dehydrogenase (LDH) is a stable enzyme 
present in all cell types, and rapidly released into cell culture medium 
upon damage of the plasma membrane. LDH therefore is the most widely 
used marker in cytotoxicicity study. 
The MTS assays demonstrated that normal and malignant breast tissue 
can be kept alive for 96 hours in culture conditions. This was also 
supported by the LDH assay technique using triton as a positive control. 
Again malignant and normal breast tissues were found to be alive at 96 
hours, although there was an increase in the LDH levels at 96 hours in 
both the normal and malignant breast tissue. In our study we only 
performed MTS assays on 9 normal and 9 breast tumour samples. In 
order to expand this study, more samples of breast tissue should be used 
in primary breast explant culture to study the effects of IGF-1 and GH on 
gene expressions of IGF-1R, PCNA, VEGF, Vitamin D, hTERT, GHR, 
Somatostatin, cox-2 gherlin and IGFBP-3. There are advantages to using 
samples of normal and malignant breast tissue that have been kept alive 
for 96 hours. It gives much more detail on how real breast tissue would 
react to the effects of IGF-1 or GH, compared to using cell lines, which 
have previously undergone mutations and may not be physiologically 
relevant. 
 Normal and malignant breast tissue was then cultured in media only or 
ghrelin. The IGF-1 mRNA expression was markedly reduced when breast 
tissue was cultured with ghrelin compared to media only. This is difficult 
to explain and may be due to the paracrine or autocrine effects of ghrelin 
on breast tissue directly rather than via the associated release of GH from 
146 
 
the pituitary gland. It has been shown in a previous paper that ghrelin 
causes a significant inhibition of cell proliferation in three different 
human breast cancer cell lines (MCF7, T47D and MDA-MB231) by 
binding to GH secretagogue receptors14. This would tie in with the 
marked reduction in IGF-1 that we found. 
 
 
Microarray 
 
Gene expression profiling by microarray analysis has identified breast 
cancer signatures that are important for prognosis and treatment. 
Microarray data has been widely used to discover biomarkers predictive 
of response to endocrine therapy in oestrogen receptor-positive breast 
cancer158. Indeed microarray is convenient and feasible for the analysis of 
IGF-1 expression in breast cancer, however a study has shown no 
significant correlation of the IGF-1 expression with the overall survival 
rate of patients159. We performed microarray on one IGF-1 positive and 
one IGF-1 negative breast cancer specimen. Figure 25 shows the image 
acquisition and data analysis which is the final step of microarray 
experiments. The aim is to produce an image of the surface of the 
hybridized array. The slide is dried and placed into a laser scanner to 
determine how much labeled cDNA (probe) is bound to each target spot. 
Laser excitation of the incorporated targets yields an emission with 
characteristic spectra, which is measured using a confocal laser 
microscope. The microarray software has used blue lines on the 
microarray to represent genes upregulated in the experimental sample, red 
to represent genes that are downregulated in the experimental sample, and 
white to represent those genes of equal abundance in both IGF-1 positive 
and IGF-1 negative samples. 
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There were 39 genes which seemed to be over expressed in IGF-1 
positive breast cancer. These include tubulin alpha 3, which has been 
previously found to be overexpressed in malignant breast tumours 
immunohistochemically160 Transforming growth factor beta 1, a 
multifunctional peptide that controls proliferation and differentiation, was 
also upregulated 2.15 fold in the IGF-1 positive tumours161. In addition it 
has been shown to promote the formation of lung metastases in animal 
models of breast cancer161. We also found an over expression of 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM 1) 
in the IGF-1 positive breast tumour which was upregulated 3.35 fold. 
CEACAM is known to be an intracellular adhesion molecule that is 
known to be over expressed in a variety of human cancers including 
colon, breast and lung. It exhibits marked angiogenic properties in vitro 
and in vivo and it is associated with tumourigensis, tumour cell adhesion 
invasion and metastasis162. One the genes down regulated (<2fold) in the 
IGF-1 positive tumours was suppression of tumourigenicity 13. This is an 
abundant highly conserved protein that binds heat shock protein and has 
previously been shown to be down regulated in breast, colorectal and 
ovarian carcinoma163. Further classification of the genes up regulated in 
IGF-1 positive breast cancers will help to elucidate the mechanisms by 
which IGF-1 influences the pathogenesis of breast cancer.  
We only performed microarray on 2 breast tumour samples. This was due 
to the expense of the microarray chips and the limitations of microarray, 
with it being non-quantitive and semi-accurate. The advantage of 
microarray is that it shows information regarding many genes affected. In 
order to expand this study I would perform microarray on a greater 
number of IGF-1 positive and negative breast tumour samples and look at 
the clinical relevance regarding IGF-1 status and the difference in gene 
expression between IGF-1 positive and negative tumours.  
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Clinical potential 
 
The major role played by the GH/IGF-1 axis in the development and 
behaviour of breast cancer and its interaction with estrogens may have 
important clinical implications. As serum IGF-1 appears to be a major 
determinant of subsequent breast cancer development, measurements of 
its levels may be of predictive value in assessing future breast cancer risk. 
It may also lead to chemopreventation through serum IGF-1 reduction.  
Targeting the GH/IGF-1 axis might also be of value in the development 
of novel treatments for breast cancer. Several strategies are currently 
being employed to inhibit IGF signalling: monoclonal antibodies against 
the IGF-1 receptor inhibit breast cancer cell proliferation in vitro and 
block the mitogenic effects of exogenous IGF-1129. This blockade also 
inhibits the in vivo growth of estrogen-independent breast cancer cells129. 
Dominant negative mutants of the IGF-I receptor suppress adhesion and 
invasion of breast cancer cell lines164. Selective inhibitors of the IGF-1 
receptor also inhibit proliferation and enhance apoptosis by increasing the 
response of tumour cells to ionising radiation165 The IGF-1 receptor can 
also be targeted by small molecular inhibitors of the IGF-1R tyrosine 
kinase, and molecular agents such as antisense and small interfering 
RNAs127;166. Dalotuzumab is a recombinant humanized monoclonal 
antibody targeted against IGF-1 receptor which has been used for the 
potential intravenous treatment of cancer167. It acts by inhibiting IGF-1 
and IGF-2 mediated tumour cell proliferation, IGFR-1 
autophosphorylation and Akt phosphorylation. In multiple cancer cell 
lines and in mouse xenograft models, dalotuzumab displays significant 
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antitumour activity, in particular against breast cancer. In addition 
coadministration of Dalotuzumab with other anti cancer agents, such as 
Taxanes enhanced the in vivo and in vitro antitumour activity of 
dalotuzumab. At the moment several clinical trials are undergoing to 
evaluate Dalotuzumab use alone and in combination with other anticancer 
agents to treat several solid tumours167.An alternative, but less practical 
method for reducing IGF-1 action is to limit its bioavailabilty by 
transfection of IGFBPs168;169.  
Somatostatin analogues exert antiproliferative effects both in vivo and in 
vitro, in part by inhibiting GH release and therefore reducing IGF-I 
levels, eg octreotide reduces breast cancer growth by 50% in mice3. 
However, the results in humans have been disappointing, and no study 
has reported either an objective tumour response or a significant 
difference in overall or disease-free survival170-172. It is possible that 
combination therapy with tamoxifen, octreotide and a prolactin antagonist 
might be more beneficial173. 
To date the most potent therapy for reducing serum IGF-1 levels is 
Pegvisomant, the novel GH-receptor antagonist174. It is intriguing that in 
nude mice xenografted with human colorectal cancer cell lines, 
Pegvisomant treatment caused a 39% reduction in tumour volume and a 
44% reduction in tumour weight175. Pegvisomant also demonstrates 
inhibitory effects against breast cancer cell lines implanted into athymic 
mice176. Whether this can be translated to human breast cancer in vivo 
remains to be seen.  
A major cause of recurrence and treatment failure in breast cancer is the 
development of resistance to oestrogen manipulation. The significant 
cross talk between IGF-1 and oestrogen-mediated signalling has been 
proposed as an important mechanism for the development of this 
resistance177. Therefore targeting the IGF-1 pathway may be a novel 
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approach to overcoming this resistance. A study has shown the inhibition 
of the IGF-1R pathway and aromatase to be synergistic in two 
independent oestrogen-dependant in vitro models of breast cancer178. 
More over synergism of a selective IGF-1R inhibitor (NVP-AEW541) 
and letrozole correlated with induction of apoptosis. Therefore 
combination of IGF-1R inhibitors and letrozole may hold promise for the 
treatment of patients with oestrogen-dependent breast cancer. 
Similarly, it has been suggested that the IGF-1 signalling pathway also 
interferes with the antiproliferative actions of trastuzumab179. 
Trastuzumab (Herceptin) is a humanized monoclonal antibody directed 
against the extracellular domain of the tyrosine kinase receptor ERBB2. 
ErbB2 is a member of the epidermal growth factor receptor family and 
has been implicated in cellular proliferation, apoptosis and angiogenesis. 
It is overexpressed in 25-30% of breast cancers and is associated with an 
aggressive phenotype and poor prognosis. Trastuzumab is an effective 
inhibitor of the growth of breast cancers overexpressing ErbB2, although 
not all respond and most become resistant within 12 months. This is 
associated with increased signalling through the IGF-I receptor179. In 
addition, IGF-I and ErbB2 receptors are known to heterodimerise. The 
resultant activated receptor cannot bind trastuzumab and consequently 
deregulated signalling from this heterodimer occurs180. Confirmation of 
an association between IGF-I receptor activation and resistance to 
trastuzumab would support a future role for combination treatment with 
anti-IGF-I receptor and anti-ErbB2 therapies181. 
Overexpression of IGF-1R has been shown to reduce trastuzumab-
mediated growth arrest of HER2-overexpressing breast cancer cells179. In 
addition it has been shown that IGF-1R induces phosphorylation of HER2 
specifically in trastuzumab-refractory breast cancer cells180. IGF-1R 
blockade using a specific kinase inhibitor, antibody, or IGF-1 binding 
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protein restored trastuzumab response to resistant cells179;180. This 
supports the importance of the IGF-1 signalling pathway in trastuzumab 
resistance. 
Further study has shown that the phenolic compound 
nordihydroguaiaretic acid (NDGA) promoted cell death of tratuzumab-
naive and trastuzumab-refractory HER2-overexpressing breast cancer cell 
lines182. NDGA has been shown to induce DNA fragmentation, cleavage 
of poly (ADP-ribose) polymerase and caspase-3, and inhibition of colony 
formation. Combination treatment with NDGA and trastuzumab 
suppresses proliferation and survival of trastuzumab-refractory cells to a 
greater degree than either agent alone. This suggests that NDGA 
increases the sensitivity of refractory cells to trastuzumab. Derivatives of 
NDGA are currently in clinical trial for other solid tumours. The data 
strongly suggests the further study of NDGA as a potential therapeutic 
against breast cancers that have progressed on trastuzumab182. 
 
Ultimately the GH/IGF-1 axis has been shown to play an important role 
in both normal mammary development and carcinogenesis. It is possible 
that measuring serum IGF-1 and IGFBP-3 levels may prove to be useful 
in women at increased risk of developing breast cancer, and may provide 
useful information should breast cancer subsequently develop. However 
further clinical trials are required, with larger numbers of patients, to 
determine the detailed effects of IGF-1R antagonists, GH antagonists and 
somatostatin agonists in the treatment of breast cancer. 
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 8. Conclusion 
 
We have shown the expression of IGF-1 in normal and malignant breast 
tissue, with the Ribogreen method showing that breast tumours produce 
3-4 times more IGF-1 RNA than normal breast tissue. Interestingly, 
looking at our RT-PCR results, it showed that IGF-1 mRNA was 
significantly down regulated in breast tumours compared to normal breast 
tissue. This may be accounted for by the large number of cells present in 
breast tissue, which may affect the results. This may indicate a place for 
laser capture microdissection so that mRNA from only breast tumour 
cells can be examined. My research has shown expression of IGF-1R, 
PCNA, VEGF-165, Vitamin D receptor and HTERT all to be over 
expressed in breast tumour tissue compared to normal breast tissue. The 
up regulation of these genes fits in with the cell proliferation, 
angiogenesis and reduced apoptosis that occurs in malignant tissue. It also 
explains the importance of developing selective inhibitors to the IGF-1R, 
such as Dalotuzumab, which is currently undergoing several clinical trials 
into the treatment of breast cancer. 
In summary, using a viable system for keeping normal and malignant 
breast tissue alive for up to 96 hours, using immunohistochemical 
staining of IGF-1,  looking at serum levels of IGF-1 in women with breast 
cancer, and using microarray, we have established a role for the GH-IG-1 
axis in the development and progression of breast cancer. This indicates 
the role for a novel treatment for breast cancer using antagonists to the 
GH-IGF-1 axis. 
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Appendix B. Patient 
tumour 
characteristics 
         
             
Sample  
No. 
Specimen Patient 
age 
Prev 
op 
Previous Histol Histol Size Grade LN Vasc 
inv 
Associated
DCIS 
ER PR 
100N Right 
Prophylactic 
mastectomy 
49 yes  R WLE+AC. 
2.8cm G3 0/10 
LN ER+PR+ 
no  
cancer 
n/a n/a none none none no no 
101N/T Left mast 
and AC 
68 no none IDC 16mm 3 1/10 
micomet 
yes HGDCIS 0 0 
102N/T Left WLE 
and AC 
45 no none IDC 25mm 2 1/15 LN yes HGDCIS 8 7 
103N/T Right mast 
and AC 
94 yes R WLE+AS. 
IDC G2 0/3LN. 
Recurrence 
axillary tail 
IDC 7mm 2 4/12 LN yes none 7 8 
104N/T Left mast 
and AC 
61 no none DCIS 14mm n/a 0/12 LN no DCIS 8 8 
105N/T Right WLE 
and AC 
54 no none IDC 23mm 2 2/14 LN no HGDCIS 8 8 
106N/T Left WLE 
and AC 
50 no none Tub+lob 13mm 1 0/11 LN no DCIS 7 5 
107N/T Left WLE 
and AC 
65 no none IDC 14mm 2 0/13 LN no none 8 4 
108N/T Left WLE 
and AC 
67 no none IDC 9mm 2 0/12 LN no DCIS 8 7 
109N/T Left mast 
and AC 
83 no none IDC 21mm 2 0/15 LN no none 7 8 
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110N/T Right WLE 
and AC 
31 no none IDC 17mm 2 1/14 
LN 
no no 8 5 
111N/T Right WLE 
and AS 
78 yes Left breast - 
fibroadenosis
IDC 13mm 2 0/4 LN no no 0 0 
112N Bilat proph 
mastectomy 
72 no none hyperplasia n/a n/a none no no no no 
113N/T Right WLE 
and AS 
77 no none IDC 15mm 2 1/17 
LN 
no DCIS 7 6 
114N/T Right WLE 
and AS 
56 no none IDC 8mm 1 0/19 
LN 
no DCIS 7 8 
115N/T Left mast 
and AC 
88 no none IDC 15mm 1 0/9 LN no no 8 7 
116N/T Right WLE 
and AC 
77 no none Tubular 18mm 1 0/15 
LN 
no DCIS 8 8 
117N/T Right WLE 
and AC 
91 no none IDC 23mm 1 0/6 LN no no 8 8 
118N/T Left mast 
and LD 
recon 
58 no none Ductal+lob 53mm 2 none yes no 6 3 
119N Right WLE 60 no none radial scar 21mm n/a none no no no no 
120N/T Left WLE 
and AS 
66 no none IDC 8mm 1 0/5 LN no HGDCIS 8 8 
121N/T Right WLE 
and AS 
61 no none IDC 14mm 3 1/6 LN no DCIS 6 7 
122N/T  Left mast 
and AC 
71  no  none  lobular  55mm 2 16/18  yes no  8  6 
123N/T  Right WLE 
and AC 
73  no  none  IDC  12mm 2 0/23 LN no  HGDCIS  8  6 
124N/T  Right mast 
and AC 
49  no  none  IDC  40mm 3 4/15 LN yes HGDCIS  5  8 
125N/T  Right WLE 
and AC 
40  no  none  IDC  18mm 2 8/20 LN yes DCIS  8  8 
126N/T  Right WLE 
and As 
60  no  none  Tubular  11mm 1 0/4 LN  no  no  7  8 
127N/T  Right mast 
and AC 
77  no  none  IDC  16mm 3 19/19 
LN 
yes HGDCIS  0  0 
 
128N/T Right WLE 
and AC 
45 no none AMC 22mm 3 0/14 
LN 
yes no 0 3 
129N/T Right WLE 
and AC 
87 no none IDC 23mm 3 0/15 
LN 
no no 8 4 
130N/T Right 
mastectomy 
45 yes G3 IDC 
0/12 LN 
IDC 29mm 2 none no DCIS 7 7 
131N/T Left WLE 
and AC 
76 no none mucinous 15mm 1 0/28 
LN 
no no 7 7 
132N/T Right WLE 76 no none IDC 16mm 3 none yes HGDCIS 8 8 
133N/T Right WLE 
and AC 
64 no none IDC 21mm 2 15/18 
LN 
yes HGDCIS 0 0 
134N/T Left WLE 
and AS 
82 no none mucinous 11mm 2 0/3 LN no no 8 6 
135N/T Right mast 
and AC 
71 no none Ductal+lob 10mm 2 1/10 
LN 
yes DCIS 7 7 
136N/T Left WLE 
and AC 
86 no none IDC 20mm 3 0/14 
LN 
no DCIS 8 7 
137N/T Left mast 
and AC 
78 no none IDC 20mm 3 2/11 
LN 
no DCIS 7 4 
138N/T Right WLE 
and AC 
84 no none DCIS 16mm n/a 0/9 LN no DCIS 7 6 
139N Right 
compl mast 
65 yes 11mm G3 
IDC 
none n/a n/a none no no no no 
140N/T Left WLE 
and AC 
85 no none IDC 24mm 2 1/18 
LN 
on DCIS 7 4 
141N/T Left WLE 
and AS 
65 no none IDC 10mm 3 1/11 
LN 
no HGDCIS 0 0 
142 
N/T 
Right WLE 
and AC 
80 no none IDC 11mm 3 1/15 
LN 
yes HGDCIS 8 0 
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143N/T Right mast 
and AC 
67 no none IDC 70mm 3 2/12 
LN 
yes HGDCIS 7 6 
 
 
144N/T Left mast 
and AC 
49 no none IDC 50mm 2 5/14 
LN 
yes HGDCIS 6 5
145N/T Left WLE 
and AC 
64 no none Tubular 22mm 1 1/11 
LN 
no no 8 8
146N/T Left compl 
mast 
79 yes 12mmG2 
IDC 
Ductal+lob 19mm 3 0/2 LN yes no 7 5
147N/T Left mast 
and AC 
48 no none IDC 10mm 1 0/30 
LN 
no DCIS 8 5
148N/T Right WLE 
and AS 
61 no none Tubular 16mm 1 0/4 LN no no 6 4
149N Right WLE 
and AS 
60 no none IDC 9mm 2 0/5 LN yes DCIS 8 8
150N/T Right mast 
and AC 
50 no none IDC 24mm 2 2/22 
LN 
no DCIS 7 6
151N Right 
compl mast 
53 yes 23mmG2 
IDC  
DCIS 2mm n/a none no DCIS 8 8
152N/T Left mast 
and AS 
58 no none HGDCIS 9mm n/a 0/1 LN no HGDCIS 6 4
153N/T Left mast 
and AS 
58 no none HGDCIS 5mm n/a 0/4 LN no HGDCIS 7 8
154N Left WLE 
and AS 
71 no none IDC 7mm 1 0/7 LN no DCIS 8 8
155N/T Right mast 
and AC 
77 no none IDC 60mm 3 0/18 
LN 
no no 0 0
156N/T Right mast 
and AC 
67 yes G2  
0/2LN 
IDC 42mm 3 19/19 
LN 
yes no 4 0
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157N/T Left 
mastand 
AC 
87 no non IDC 25mm 3 0/10LN no no 0 0
158N Right WLE 
and SLNB 
67 no none IDC 7mm 3 0/4 LN no DCIS 7 7
159N Right mast 
and AC 
71 yes G3 IDC Fibrotic n/a n/a 0/10 
LN 
no no no no
160N/T Left mast 
and AC 
40 no none Ductal+lob 18mm 1 0/15 
LN 
no DCIS 7 8
161N/T Right WLE 
and AC 
91 no none IDC 20mm 2 0/9 LN no no 8 8
162N/T Left WLE 
and AS 
71 no none IDC 17mm 3 3/8 LN no HGDCIS 7 6
163N Right WLE 
and AS 
61 no none IDC 5mm 3 4/5 LN no HGDCIS 6 4
164N/T Left compl 
mast 
72 yes G3 21mm 
IDC 0/9 
LN 
IDC 45mm 3 none yes DCIS 0 0
165N Right WLE 71 yes DCIS DCIS 15mm n/a none no DCIS 7 6
166N/T Right WLE 
and AS 
76 no none IDC 16mm 2 1/5 LN no DCIS 0 0
167N/T Right mast 
and AC 
48 yes DCIS IDC 28mm 3 1/9 LN yes no 5 8
168N Left breast 
reduction 
54 yes 9mm G1 
IDC 0/6 
LN 
Fibrocystic n/a n/a none no no no no
169N Left WLE 68 yes G2 IDC 
4/8 LN  
HGDCIS 2mm n/a none no HGDCIS 6 4
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170N Right WLE 
and AS 
66 yes  radial 
scar 
IDC 8mm 2 0/4 LN no HGDCIS 7 7
171N Proph bilat 
mast 
62 no none Fibrocystic  n/a n/a 0/14 
LN 
no no no no
172N/T Left WLE 
and AC 
56 no none Squamous 19mm 3 2/24 
LN 
no HGDCIS 4 4
173N/T Right mast 66 yes 8mm IDC Ductal+lob 8mm 2 none no DCIS 7 8
174N/T Left mast 
and AS 
76 yes G2 IDC 
1/11LN  
HGDCIS 22mm n/a 1/4 LN yes HGDCIS 0 2
175N/T Right mast 
and AC 
86 yes left mast ILC 35mm 2 0/7 LN no no 8 5
176N/T Right WLE 
and AC 
74 no none HGDCIS 19mm 3 0/15 
LN 
yes HGDCIS 0 3
177N Left breast 
reduction 
65 yes G3 IDC Hyperplasia n/a n/a none no no no no
178N/T Left WLE 
and AS 
48 no none IDC 15mm 2 1/4 LN no DCIS 7 4
179N Right mast 
and AS 
63 no none IDC 21mm 1 0/8 LN no DCIS 8 8
180N Left WLE  77 no none HGDCIS 35mm n/a none no HGDCIS 0 0
181N/T Right WLE 
and AC 
81 no none IDC 13mm 1 0/10 
LN 
no no 7 7
182N/T Right mast 
and AC 
71 no none IDC 50mm 3 12/20 
LN 
no no 7 8
183N/T Right mast 
and AC 
51 no none Ductal+lob 22mm 3 2/10 
LN 
yes DCIS 7 8
184N/T Left mast 
and AS 
57 no none IDC 9mm 2 0/4 LN no DCIS 7 8
185N/T Left mast 87 no none ILC 75mm 2 4/14 no DCIS 7 2
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and AC LN 
186N/T Right 
mastectomy 
72 yes 21mm G2 
IDC 
Ductal+lob 15mm 2 none no no 7 4
187N/T Left mast 
and AS 
60 no none IDC 8mm 3 0/6 LN yes HGDCIS 4 7
188N/T Left 
mastectomy 
84 no none IDC 11mm 3 0/7 LN no DCIS 8 7
189N/T Left WLE 
and AS 
64 no none Ductal+lob 14mm 1 0/5 LN no no 7 7
190N/T Left mast 
and AC 
39 no none IDC 32mm 3 2/12 
LN 
no HGDCIS 6 8
191N/T Right mast 
and AC 
79 no none Ductal+lob 18mm 2 2/11 
LN 
no HGDCIS 7 4
192N/T Right mast 
and AC 
54 no none ILC 28mm 1 0/12 
LN 
no DCIS 7 4
193N/T Left 
mastectomy 
69 yes fibrocystic maligant 
phyllodes 
60mm n/a none no no no no
194N/T Left mast 
and AS 
65 no none ILC 8mm 2 0/2 LN no LCIS 7 6
195N/T Left WLE 
and AS 
67 no none IDC 22mm 2 0/6 LN no no 7 7
196N/T Right mast 
and AC 
63 no none IDC 19mm 3 1/9 LN yes HGDCIS 5 7
197N/T Left WLE 
and AC 
70 no none IDC 35mm 2 0/18 
LN 
no DCIS 6 5
198N Exc right 
breast lump 
33 no none Fibroadenoma n/a n/a none no no no no
199N Exc right 38 no none Hamartoma n/a n/a none no no no no
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breast lump 
200N Exc right 
breast lump 
41 no none Fibroadenoma n/a n/a none no no no no
201N Left 
reduction 
mastectomy 
63 yes right 
WLE and 
AC 
Fibrocystic 
change 
n/a n/a none no no no no
202N/T Left mast 
and AC 
79 no none IDC 80mm 3 0/12 
LN 
no no 0 0
203N/T Right mast 
and AC 
48 no none IDC 20mm 3 4/9 LN yes DCIS 0 2
204N/T Right WLE 
and AC 
83 no none IDC 24mm 3 1/10 
LN 
no DCIS 7 5
205N/T Right mast 
and AC 
61 yes benign 
lump 
IDC 15mm 1 1/10 
LN 
no no 8 8
206N/T Right mast 
and AC 
60 no none IDC 19mm 3 0/12 
LN 
no no 5 6
207N Exc right 
breast lump 
38 no none Hamartoma n/a n/a none no no no no
208N Exc right 
breast lump 
26 no none Fibroadenoma n/a n/a none no no no no
209N/T Right WLE 
and AC 
81 no none IDC 30mm 2 6/6 LN no no 8 0
210N/T Left WLE 
and AC 
50 no none IDC 27mm 3 0/13 
LN 
no no 0 0
211N Proph left 
mast 
78 yes 12mm 
DCIS 
fibrosis n/a n/a none no no no no
212N/T Right mast 
and AC 
87 no none IDC 40mm 3 10/16 
LN 
yes HGDCIS 0 0
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213N/T Right 
mastectomy 
75 yes  R WLE 
and AC 
IDC 12mm 3 none no no 0 3
214N Exc right 
breast lump 
42 no none fibrosis n/a n/a none no no no no
215N Exc left 
breast lump 
38 no  none Hamartoma n/a n/a none no no no no
216N Exc right 
breast lump 
28 no none Hamartoma n/a n/a none no no no no
217N/T Left WLE 
and AC 
82 no none IDC 16mm 2 2/19 
LN 
no HGDCIS 8 6
218N/T Left WLE 
and AC 
61 no none Muscinous 40mm 2 0/9 LN no DCIS 8 8
219N/T Right WLE 
and AC 
43 no none IDC 3mm 3 0/9 LN no HGDCIS 0 0
220N/T Left mast 
and AC 
59 no none IDC 45mm 3 1/12 
LN 
yes DCIS 8 6
221N Exc of right 
breast lump 
26 no none Fibroadenoma n/a n/a none no no no no
222N/T Left mast 
and AC 
66 no none IDC 14mm 2 0/17 
LN 
no DCIS 6 6
223N/T Left WLE 
and AC 
57 no none IDC 26mm 3 0/13 
LN 
no DCIS 7 8
224N Exc left 
breast lump 
40 no none Fibroadenoma n/a n/a none no no no no
225N/T Left mast 
and AC 
41 no none IDC 50mm 2 0/16 
LN 
no HGDCIS 8 4
226N/T Left mast 
and AC 
60 no none IDC 22mm 2 14/14 
LN 
yes HGDCIS 0 0
227N Exc right 38 no  none Fibroadenoma n/a n/a none no no no no
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breast lump 
228N Proph right 
mastectomy 
60 yes Left mast 
and AC 
Normal n/a n/a none no no no no
229N Exc of left 
breast lump 
39 no none radial scar n/a n/a none no no no no
230N Exc of right 
breast lump 
25 no  none Fibroadenoma n/a n/a none no no no no
231N Exc of left 
breast lump 
75 no none Fibrofatty n/a n/a none no no no no
232N/T Right mast 
and AS 
66 no none IDC 12mm 2 0/4 LN no no 8 7
233N Exc left 
breast lump 
52 no none Hamartoma n/a n/a none no no no no
234N/T Left mast 
and AC 
78 no none Mucinous 50mm 2 4/6 LN no no 8 7
235N/T Right mast 
and AC 
76 no none ILC 16mm 2 0/15 
LN 
no DCIS 8 3
236N/T Right WLE 
and AC 
95 no none Papillary 4mm 2 0/9 LN no DCIS 8 8
237N/T Left WLE 
and AC 
71 no none IDC 19mm 3 16/18 
LN 
no no 0 0
238N/T Right mast 
and AC 
86 no none IDC 26mm 3 0/15 
LN 
no no 0 4
239N/T Left WLE 
and AC 
51 no none IDC 17mm 2 2/16 
LN 
no HGDCIS 3 8
240N/T Left mast 
and SLNB 
64 yes duct 
excision 
IDC 30mm 1 1/10 
LN 
no DCIS 8 7
241N/T Right mast 
and AC 
68 yes G3 IDC IDC 11mm 3 0/6 LN no DCIS 7 4
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242N/T Left mast 
and AC 
70 no none IDC 35mm 3 9/10 
LN 
yes no 8 0
243N/T Left mast 
and AC 
69 no none Ductal+lob 12mm 3 0/10 
LN 
no HGDCIS 8 7
244N/T L mast and 
AC 
60 no none IDC 17mm 2 0/11 
LN 
no HGDCIS 6 7
245N/T Left WLE 
and AC 
67 no none IDC 27mm 3 0/11 
LN 
no LCIS 0 0
246N/T Right mast 
and AC 
58 no none IDC 45mm 3 1/13 
LN 
yes HGDCIS 7 3
247N Exc right 
breast lump 
45 no none Hamartoma n/a n/a none no no no no
248N/T Left mast 
and AC 
70 no none IDC 60mm 3 2/15 
LN 
yes DCIS 8 8
249N/T Left mast 
and AC 
69 yes mastect IDC 14mm 3 0/7 LN no HGDCIS 0 0
250N Right mast 
and AC 
72 no none IDC 40mm 3 5/15 
LN 
no DCIS 4 2
251N Exc right 
breast lump 
39 no none Hamartoma n/a n/a none no no no no
252N Exc left 
breast lump 
25 no none Fibroadenoma n/a n/a none no no no no
253N/T Right mast 
and AC 
58 no none IDC 12mm 3 0/15 
LN 
no HGDCIS 0 0
254N Left breast 
reduction 
38 no none Normal n/a n/a none no no no no
255N Exc left 
breast lump 
69 no none Normal n/a n/a none no no no no
256N Exc left 37 no none Fibroadenoma n/a n/a none no no no no
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breast lump 
257N Exc left 
breast lump 
40 no none Normal n/a n/a none no no no no
258N/T Left mast 
and AC 
59 no none IDC 70mm 3 14/16 
LN 
yes HGDCIS 0 0
259N/T Left mast 
and AC 
66 yes Right 
mast+AC 
Papillary 35mm 2 0/10 
LN 
no no 0 0
260N Bilat  breast 
reduction 
44 no none Normal n/a n/a none no no no no
261N Exc right 
breast lump 
36 no none Fibroadenoma n/a n/a none no no no no
262N Exc right 
breast lump 
51 no none Fibroadenoma n/a n/a none no no no no
263N Exc left 
breast lump 
46 no none Fibrosis n/a n/a none no no no no
264N/T Right mast 
and SLNB 
60 no none IDC 12mm 1 0/5 LN no no 7 2
265N Exc left 
breast lump 
28 no none Fibroadenoma n/a n/a none no no no no
266T Exc left 
breast lump 
62 yes Left mast IDC 10mm 2 none no no 6 7
267N/T Left WLE 78 yes Left mast ILC 12mm 2 none no no 0 0
268N Exc left 
breast lump 
68 no none Lipoma n/a n/a none no no no no
269N/T Left mast 
and AS 
64 no none IDC 13mm 2 0/4 LN no DCIS 5 5
270N Right WLE 28 no none Hamartoma n/a n/a none no no no no
271N/T Exc right 
breast lump 
48 no none IDC 8mm 1 none no no 0 0
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272N Exc left 
breast lump 
59 no none Inflamed  cyst n/a n/a none no no no no
273N/T Left mast 
and AC 
85 no none IDC 19mm 3 0/7 LN no HGDCIS 8 5
274N/T Right WLE 
and AC 
74 no none IDC 33mm 3 10/19 
LN 
yes DCIS 8 8
275N/T Left WLE 
and AC 
50 no none IDC 17mm 3 0/15LN no no 0 0
276N/T Left mast 
and AC 
80 no none IDC 66mm 3 1/14 
LN 
no DCIS 8 5
277N/T Right mast 
and AC 
53 no none IDC 18mm 2 5/5 LN no no 7 4
278N/T Right mast 
and AS 
60 yes R WLE  IDC 22mm 3 2/11 
LN 
no no 7 6
279N/T Left compl 
mast 
60 yes 18mm G3 
IDC 
IDC 13mm 3 none no HGDCIS 7 6
280N/T Right mast 
and AC 
57 no none IDC 22mm 3 1/19 
LN 
no no 0 0
281N/T Left mast 
and AS 
59 no none IDC 18mm 2 0/4 LN no DCIS 7 8
282N Exc left 
breast lump 
29 no none Fibroadenoma n/a n/a none no no no no
283N Exc right 
breast lump 
28 no none Fibroadenoma n/a n/a none no no no no
284N Exc right 
breast lump 
34 no none Hamartoma n/a n/a none no no no no
285N/T Left mast 
and AC 
70 no none IDC 16mm 2 0/15 
LN 
no DCIS 6 7
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